Specific Forms of Anemia

WHO. World prevalence of anaemia 1993–2005. WHO Global Database on Anaemia 2008.Google Scholar

Black, RE, Allen, LH, Bhutta, ZA, Caulfield, LE, de Onis, M, Ezzati, M, Mathers, C, et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet. 2008; 371:243–260.Google Scholar

Ganz, T, Nemeth, E. Iron metabolism: interactions with normal and disordered erythropoiesis. Cold Spring Harb Perspect Med. 2012; 2:a011668.CrossRef Google Scholar PubMed

Ganz, T, Nemeth, E. Hepcidin and iron homeostasis. Biochim Biophys Acta. 2012; 1823:1434–1443.Google Scholar

Miller, JL. Iron deficiency anemia: a common and curable disease. Cold Spring Harb Perspect Med. 2013; 3.CrossRef Google Scholar PubMed

Andrews, NC. Forging a field: the golden age of iron biology. Blood. 2008; 112:219–230.CrossRef Google Scholar PubMed

Hentze, MW, Muckenthaler, MU, Andrews, NC. Balancing acts: molecular control of mammalian iron metabolism. Cell. 2004; 117:285–297.Google Scholar

Pigeon, C, Ilyin, G, Courselaud, B, Leroyer, P, Turlin, B, Brissot, P, Loreal, O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001; 276:7811–7819.CrossRef Google Scholar PubMed

Bolondi, G, Garuti, C, Corradini, E, Zoller, H, Vogel, W, Finkenstedt, A, Babitt, JL, et al. Altered hepatic BMP signaling pathway in human HFE hemochromatosis. Blood Cells Mol Dis. 2010; 45:308–312.CrossRef Google Scholar PubMed

Kemna, E, Pickkers, P, Nemeth, E, van der Hoeven, H, Swinkels, D. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood. 2005; 106:1864–1866.CrossRef Google Scholar PubMed

Nemeth, E, Rivera, S, Gabayan, V, Keller, C, Taudorf, S, Pedersen, BK, Ganz, T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004; 113:1271–1276.Google Scholar

Nicolas, G, Chauvet, C, Viatte, L, Danan, JL, Bigard, X, Devaux, I, Beaumont, C, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110:1037–1044.Google Scholar

Andriopoulos, B Jr., Corradini, E, Xia, Y, Faasse, SA, Chen, S, Grgurevic, L, Knutson, MD, et al. BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet. 2009; 41:482–487.Google Scholar

Verga Falzacappa, MV, Casanovas, G, Hentze, MW, Muckenthaler, MU. A bone morphogenetic protein (BMP)-responsive element in the hepcidin promoter controls HFE2-mediated hepatic hepcidin expression and its response to IL-6 in cultured cells. J Mol Med (Berl). 2008; 86:531–540.CrossRef Google Scholar PubMed

Zhang, AS, Anderson, SA, Meyers, KR, Hernandez, C, Eisenstein, RS, Enns, CA. Evidence that inhibition of hemojuvelin shedding in response to iron is mediated through neogenin. J Biol Chem. 2007; 282:12547–12556.Google Scholar

Lin, L, Nemeth, E, Goodnough, JB, Thapa, DR, Gabayan, V, Ganz, T. Soluble hemojuvelin is released by proprotein convertase-mediated cleavage at a conserved polybasic RNRR site. Blood Cells Mol Dis. 2008; 40:122–131.CrossRef Google Scholar

Silvestri, L, Pagani, A, Camaschella, C. Furin-mediated release of soluble hemojuvelin: a new link between hypoxia and iron homeostasis. Blood. 2008; 111:924–931.Google Scholar

Silvestri, L, Pagani, A, Nai, A, De Domenico, I, Kaplan, J, Camaschella, C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab. 2008; 8:502–511.Google Scholar

Lin, L, Goldberg, YP, Ganz, T. Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood. 2005; 106:2884–2889.Google Scholar

Babitt, JL, Huang, FW, Xia, Y, Sidis, Y, Andrews, NC, Lin, HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007; 117:1933–1939.Google Scholar

Du, X, She, E, Gelbart, T, Truksa, J, Lee, P, Xia, Y, Khovananth, K, et al. The serine protease TMPRSS6 is required to sense iron deficiency. Science. 2008; 320:1088–1092.Google Scholar

Nemeth, E, Tuttle, MS, Powelson, J, Vaughn, MB, Donovan, A, Ward, DM, Ganz, T, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306:2090–2093.CrossRef Google Scholar PubMed

Fraenkel, PG, Traver, D, Donovan, A, Zahrieh, D, Zon, LI. Ferroportin1 is required for normal iron cycling in zebrafish. J Clin Invest. 2005; 115:1532–1541.CrossRef Google Scholar PubMed

James, AH, Kouides, PA, Abdul-Kadir, R, Dietrich, JE, Edlund, M, Federici, AB, Halimeh, S, et al. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol. 2011; 158:124–134.CrossRef Google Scholar PubMed

Khalafallah, AA, Dennis, AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy. 2012; 2012:630519.Google Scholar

Christensen, L, Sguassero, Y, Cuesta, CB. Anemia and compliance to oral iron supplementation in a sample of children attending the public health network of Rosario, Santa Fe. Arch Argent Pediatr. 2013; 111:288–294.Google Scholar

Bregman, DB, Morris, D, Koch, TA, He, A, Goodnough, LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013; 88:97–101.Google Scholar

Auerbach, M, Ballard, H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2010; 2010:338–347.CrossRef Google Scholar PubMed

Khalafallah, AA, Dennis, AE, Ogden, K, Robertson, I, Charlton, RH, Bellette, JM, Shady, JL, et al. Three-year follow-up of a randomised clinical trial of intravenous versus oral iron for anaemia in pregnancy. BMJ Open. 2012; 2.CrossRef Google Scholar PubMed

Vaziri, ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis. 2013; 61:992–1000.Google Scholar

Bottomley, SS, Fleming, MD. Sideroblastic anemia: diagnosis and management. Hematology/Oncology Clinics of North America. 2014; 28(4):653–670. Epub 2014/07/30.Google Scholar

Mufti, GJ, Bennett, JM, Goasguen, J, Bain, BJ, Baumann, I, Brunning, R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of Myelodysplastic Syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008; 93(11):1712–1717. Epub 2008/10/08.Google Scholar

Alcindor, T, Bridges, KR. Sideroblastic anaemias. British Journal of Haematology. 2002; 116(4):733–743.CrossRef Google Scholar PubMed

McLintock, LA, Fitzsimons, EJ. Erythroblast iron metabolism in sideroblastic and sideropenic states. Hematology. 2002; 7(3):189–195. Epub 2002/09/24.CrossRef Google Scholar PubMed

Bottomley, SS, Healy, HM, Brandenburg, MA, May, BK. 5-Aminolevulinate synthase in sideroblastic anemias: mRNA and enzyme activity levels in bone marrow cells. American Journal of Hematology. 1992; 41(2):76–83.Google Scholar

Cazzola, M, Invernizzi, R, Bergamaschi, G, Levi, S, Corsi, B, Travaglino, E, et al. Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood. 2003; 101(5):1996–2000. Epub 2002/10/31.CrossRef Google Scholar PubMed

Rovo, A, Stussi, G, Meyer-Monard, S, Favre, G, Tsakiris, D, Heim, D, et al. Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood. International Journal of Laboratory Hematology. 2010; 32(3):329–335. Epub 2009/08/27.Google Scholar

Takagi, S, Tanaka, O, Origasa, H, Miura, Y. Prognostic significance of magnetic resonance imaging of femoral marrow in patients with myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1999; 17(1):277–283. Epub 1999/08/24.Google Scholar

Zarco, MA, Feliu, E, Rozman, C, Masat, T, Aymerich, M, Jou, JM, et al. Ultrastructural study of erythrocytes containing Pappenheimer bodies in a case of congenital sideroblastic anaemia (CSA). British Journal of Haematology. 1991; 78(4):577–578. Epub 1991/08/01.Google Scholar

Broseus, J, Alpermann, T, Wulfert, M, Florensa Brichs, L, Jeromin, S, Lippert, E, et al. Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia. 2013; 27(9):1826–1831. Epub 2013/04/19.Google Scholar

Parry, GJ, Bredesen, DE. Sensory neuropathy with low-dose pyridoxine. Neurology. 1985; 35(10):1466–1468. Epub 1985/10/01.Google Scholar

Malcovati, L. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. Clinical Lymphoma & Myeloma. 2009; 9 Suppl 3:S305–311. Epub 2009/09/26.Google Scholar

Broliden, PA, Dahl, IM, Hast, R, Johansson, B, Juvonen, E, Kjeldsen, L, et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica. 2006; 91(5):667–770. Epub 2006/05/04.Google Scholar PubMed

Takeuchi, M, Tada, A, Yoshimoto, S, Takahashi, K. Anemia and neutropenia due to copper deficiency during long-term total parenteral nutrition. [Rinsho ketsueki] The Japanese Journal of Clinical Hematology. 1993; 34(2):171–176. Epub 1993/02/01.Google Scholar

Iwase, O, Iwama, H, Okabe, S, Ando, K, Yaguchi, M, Miyazawa, K, et al. Refractory anemia with ringed sideroblasts with a low IPSS score progressed rapidly with de novo appearance of multiple karyotypic abnormalities and into acute erythroleukemia (AML-M6A). Leukemia Research. 2000; 24(7):597–600. Epub 2000/06/27.Google Scholar

Bernasconi, P, Alessandrino, EP, Boni, M, Bonfichi, M, Morra, E, Lazzarino, M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. American Journal of Hematology. 1994; 46(4):270–277. Epub 1994/08/01.Google Scholar

Weatherall, DJ, Clegg, JB. The Thalassaemia Syndromes, 4^th ed. Oxford, Blackwell Science; 2001.CrossRef Google Scholar

Weatherall, DJ. Thalassemia as a global health problem: recent progress toward its control in the developing countries. Ann N Y Acad Sci. 2010; 1202:17–23.Google Scholar

Patrinos, GP, Giardine, B, Riemer, C, et al. Improvements in the HbVar database of human hemoglobin variants and thalassemia mutations for population and sequence variation studies. Nucl Acids Res. 2004;32:D537–541. http://globin.cse.psu.edu/hbvar/menu.html Google Scholar

Thein, SL. The molecular basis of β-thalassemia. In: Weatherall, DJ, Schechter, AN, Nathan, DG, eds. Hemoglobin and Its Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013:159–182.Google Scholar

Verhovsek, MM, Shah, NR, Wilcox, I, et al. Severe fetal and neonatal hemolytic anemia due to a 198 kb deletion removing the complete β-globin gene cluster. Pediatr Blood Cancer. 2012; 59:941–944.Google Scholar

Olivieri, NF. The β-Thalassemias. N Engl J Med. 1999; 341:99–109.Google Scholar

Krishnamurti, L, Chui, DHK, Dallaire, M, et al. Co-inheritance of α-thalassemia-1 and hemoglobin E/β[0]-thalassemia: important implications for neonatal screening and genetic counseling. J Pediatr. 1998; 132:863–865.Google Scholar

Luo, H-Y, Chui, DHK. Diverse haematological phenotypes of β-thalassemia carriers. Ann N Y Acad Sci. 2016; 1368:49–55.Google Scholar

Cunningham, MJ, Macklin, EA, Neufeld, EJ, et al. Complications of β-thalassemia major in North America. Blood. 2004; 104:34–39.Google Scholar

Rund, D, Rachmilewitz, EA. β-Thalassemia. N Engl J Med. 2005; 353:1135–1146.Google Scholar

Rachmilewitz, EA, Giardina, PJ. How I treat thalassemia. Blood. 2011; 118:3479–3488.Google Scholar

Higgs, DR, Engel, JD, Stamatoyannopoulos, G. Thalassemia. Lancet. 2012; 379:373–383.Google Scholar

Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices Recommended Immunization Schedules for Persons Aged 0 Through 18 Years and Adults Aged 19 Years and Older—United States, 2013. MMWR. 2013; 62(Suppl 1).Google Scholar

Verhovsek, M, McFarlane, A. Abnormalities in red blood cells. In: McKean, S, ed. Principles and Practice of Hospital Medicine, 1st ed. McGraw-Hill Professional; 2012.Google Scholar

Sabloff, M, Chandy, M, Wang, Z, et al. HLA-matched sibling bone marrow transplantation for β-thalassemia major. Blood. 2011; 117:1745–1750.Google Scholar

Locatelli, F, Kabbara, N, Ruggeri, A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013; 122:1072–1078.Google Scholar

Musallam, KM, Taher, AT, Cappellini, MD, et al. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia. Blood. 2013; 121:2199–2212.CrossRef Google Scholar PubMed

Canver, MC, Orkin, SH. Customizing the genome as therapy for the β-hemoglobinopathies. Blood. 2016; 127:2536–2545.Google Scholar

Thompson, AA, Kwiatkowski, J, Rasko, J, et al. Lentiglobin gene therapy for transfusion-dependent β-thalassemia: update from the Northstar Hgb-204 phase 1/2 clinical study. Blood. 2016; 128:Abstract 1175.CrossRef Google Scholar

Thompson, AA, Kim, HY, Singer, ST, et al. Pregnancy outcomes in women with thalassemia in North America and the UK. Am J Hematol. 2013; 88:771–773.Google Scholar

Cao, A, Kan, YW. The prevention of thalassemia. In: Weatherall, DJ, Schechter, AN, Nathan, DG, eds. Hemoglobin and Its Diseases. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013:285–299.Google Scholar

Hvistendahl, M. China heads off deadly blood disorder. Science. 2013; 340:677–678.CrossRef Google Scholar PubMed

Taher, AT, Musallam, KM, Cappellini, MD, et al. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011; 152:512–523.Google Scholar

Fucharoen, S, Weatherall, DJ. The hemoglobin E thalassemias. In: Hemoglobin and Its Diseases. Weatherall, DJ, Schechter, AN, Nathan, DG, eds. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2013:229–243.Google Scholar

Cavazzana-Calvo, M, Payen, E, Negre, O, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassemia. Nature. 2010; 467:318–322.CrossRef Google Scholar

Chui, DHK, Fucharoen, S, Chan, V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003; 101:791–800.CrossRef Google Scholar

Chen, FE, Ooi, C, Ha, SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med. 2000; 343:544–550.Google Scholar

Lal, A, Goldrich, ML, Haines, DA, et al. Heterogeneity of hemoglobin H disease in childhood. N Engl J Med. 2011; 364:710–718.CrossRef Google Scholar PubMed

Tongsong, T, Srisupundit, K, Luewan, S. Outcomes of pregnancies affected by hemoglobin H disease. Int J Gynaecol Obstet. 2009; 104:206–208.Google Scholar

Lorey, F, Charoenkwan, P, Witkowska, HE, et al. Hb H hydrops foetalis syndrome: a case report and review of literature. Br J Haematol. 2001; 115:72–78.Google Scholar

Higgs, DR, Buckle, VJ, Gibbons, R, Steensma, D. Unusual types of α thalassemia. In: Disorders of Hemoglobin Genetics, Pathophysiology, and Clinical Management, 2nd ed. Steinberg, MH, Forget, BG, Higgs, DR, Weatherall, DJ, Eds. Cambridge: Cambridge University Press; 2009:296–320.Google Scholar

Steensma, DP, Gibbons, RJ, Higgs, DR. Acquired α-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005; 105:443–452.Google Scholar

Benz, EJ Jr., Wu, CC, Sohani, AR. Case records of the Massachusetts General Hospital. Case 25-2011. A 62-year-old woman with anemia and paraspinal masses. N Engl J Med. 2011; 365:648–658.CrossRef Google Scholar PubMed

Chui, DHK, Waye, JS. Hydrops fetalis caused by α-thalassemia: an emerging health care problem. Blood. 1998; 91:2213–2222.CrossRef Google Scholar PubMed

Lau, Y-L, Chan, L-C, Chan, Y-YA, et al. Prevalence and genotypes of α- and β-thalassemias in Hong Kong: implications for population screening. N Engl J Med. 1997; 336:1298–1301.Google Scholar

Peng, CT, Liu, SC, Peng, YC, et al. Distribution of thalassemias and associated hemoglobinopathies identified by prenatal diagnosis in Taiwan. Blood Cells Mol Dis. 2013; 51:138–141.CrossRef Google Scholar PubMed

Songdej, D, Babbs, C, Higgs, DR, et al. An international registry of survivors with Hb Bart’s hydrops fetalis syndrome. Blood. 2017; 129:1251–1259.Google Scholar

Leung, KY, Cheong, KB, Lee, CP, et al. Ultrasonographic prediction of homozygous α^[0]-thalassemia using placental thickness, fetal cardiothoracic ratio and middle cerebral artery Doppler: alone or in combination? Ultrasound Obstet Gynecol. 2010; 35:149–154.Google Scholar

Aslinia, F, Mazza, JJ, Yale, SH. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res. 2006; 3:236–241.Google Scholar

Kaferle, JK, Strzoda, CE. Evaluation of macrocytosis. Am Fam Phys. 2009; 79:203–208.Google Scholar

Quadros, EV. Advances in the understanding of cobalamin assimilation and metabolism. Br J Haematol. 2010; 148:195–204.Google Scholar

Andrès, E, Affenberger, S, Vinzio, S, et al. Food-cobalamin malabsorption in elderly patients: clinical manifestations and treatment. Am J Med. 2005; 118:1154–1159.Google Scholar

Neumann, WL, Coss, E, Rugge, M, Genta, RM. Autoimmune atrophic gastritis-pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol. 2013; 10:529–540.Google Scholar

Michels, AW, Gottlieb, PA. Autoimmune polyglandular syndromes. Nat Rev Endocrinol. 2010; 6:270–277.Google Scholar

Scalabrino, G, Peracchi, M. New insights into the pathophysiology of cobalamin deficiency. Trends Mol Med. 2006; 12:247–254.Google Scholar

Vannella, L, Lahner, E, Osborn, J, Annibale, B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013; 37:375–382.Google Scholar

Annibale, B, Lahner, E, Fave, GD. Diagnosis and management of pernicious anemia. Curr Gastroenterol Rep. 2011; 13:518–524.Google Scholar

Stabler, SP. Vitamin B12 deficiency. N Engl J Med. 2013; 368:149–160.Google Scholar

Kaferle, J, Strzoda, CE. Evaluation of macrocytosis. Am Fam Physician. 2009; 79:203–208.Google Scholar

Morgan, MY, Camilo, ME, Luck, W, et al. Macrocytosis in alcohol-related liver disease: its value for screening. Clin Lab Haematol. 1981; 3:35–44.Google Scholar

Garcia-Pachon, E, Padilla-Navas, I. Red cell macrocytosis in COPD patients without respiratory insufficiency: a brief report. Respir Med. 2007; 101:349–352.Google Scholar

Latvala, J, Parkkila, S, Niemelä, O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res. 2004; 28:619–624.Google Scholar

Sims, EG. Hypothyroidism causing macrocytic anemia unresponsive to B12 and folate. J Natl Med Assoc. 1983; 75:429–431.Google Scholar

Hassell, KL. Population estimates of sickle cell disease in the U.S. American Journal of Preventive Medicine. 2010;38(4 Suppl):S512–521.Google Scholar

Hofrichter, J. Kinetics of sickle hemoglobin polymerization. III. Nucleation rates determined from stochastic fluctuations in polymerization progress curves. Journal of Molecular Biology. 1986;189(3):553–571.Google Scholar

Steinberg, MH. Genetic etiologies for phenotypic diversity in sickle cell anemia. The Scientific World Journal. 2009;9:46–67.CrossRef Google Scholar PubMed

Ballas, SK. Pathophysiology and principles of management of the many faces of the acute vaso-occlusive crisis in patients with sickle cell disease. European Journal of Haematology. 2014.Google Scholar

Ballas, SK, Gupta, K, Adams-Graves, P. Sickle cell pain: a critical reappraisal. Blood. 2012;120(18):3647–3656.Google Scholar

Latremoliere, A, Woolf, CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. The Journal of Pain: Official Journal of the American Pain Society. 2009;10(9):895–926.Google Scholar

Woolf, CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106(4):864–867.Google Scholar

Kohli, DR, Li, Y, Khasabov, SG, Gupta, P, Kehl, LJ, Ericson, ME, et al. Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids. Blood. 2010;116(3):456–465.Google Scholar

Davies, SC, Luce, PJ, Win, AA, Riordan, JF, Brozovic, M. Acute chest syndrome in sickle-cell disease. Lancet. 1984;1(8367):36–38.Google Scholar

Vichinsky, EP, Styles, LA, Colangelo, LH, Wright, EC, Castro, O, Nickerson, B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative study of sickle cell disease. Blood. 1997;89(5):1787–1792.Google Scholar

Gladwin, MT, Sachdev, V, Jison, ML, Shizukuda, Y, Plehn, JF, Minter, K, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. The New England Journal of Medicine. 2004;350(9):886–895.Google Scholar

Ataga, KI, Moore, CG, Jones, S, Olajide, O, Strayhorn, D, Hinderliter, A, et al. Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. British Journal of Haematology. 2006;134(1):109–115.Google Scholar

Fonseca, GH, Souza, R, Salemi, VM, Jardim, CV, Gualandro, SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. The European Respiratory Journal. 2012;39(1):112–118.Google Scholar

Kato, GJ, Martyr, S, Blackwelder, WC, Nichols, JS, Coles, WA, Hunter, LA, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. British Journal of Haematology. 2005;130(6):943–953.Google Scholar

Moser, FG, Miller, ST, Bello, JA, Pegelow, CH, Zimmerman, RA, Wang, WC, et al. The spectrum of brain MR abnormalities in sickle-cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR American Journal of Neuroradiology. 1996;17(5):965–972.Google Scholar

Pegelow, CH, Macklin, EA, Moser, FG, Wang, WC, Bello, JA, Miller, ST, et al. Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood. 2002;99(8):3014–3018.Google Scholar

Berkelhammer, LD, Williamson, AL, Sanford, SD, Dirksen, CL, Sharp, WG, Margulies, AS, et al. Neurocognitive sequelae of pediatric sickle cell disease: a review of the literature. Child Neuropsychology: A Journal on Normal and Abnormal Development in Childhood and Adolescence. 2007;13(2):120–131.Google Scholar

Kral, MC, Brown, RT, Connelly, M, Cure, JK, Besenski, N, Jackson, SM, et al. Radiographic predictors of neurocognitive functioning in pediatric sickle cell disease. Journal of Child Neurology. 2006;21(1):37–44.Google Scholar

Steen, RG, Xiong, X, Mulhern, RK, Langston, JW, Wang, WC. Subtle brain abnormalities in children with sickle cell disease: relationship to blood hematocrit. Annals of Neurology. 1999;45(3):279–286.Google Scholar

Steen, RG, Miles, MA, Helton, KJ, Strawn, S, Wang, W, Xiong, X, et al. Cognitive impairment in children with hemoglobin SS sickle cell disease: relationship to MR imaging findings and hematocrit. AJNR American Journal of Neuroradiology. 2003;24(3):382–389.Google Scholar

Iampietro, M, Giovannetti, T, Tarazi, R. Hypoxia and inflammation in children with sickle cell disease: implications for hippocampal functioning and episodic memory. Neuropsychology Review. 2014;24(2):252–265.Google Scholar

Ohene-Frempong, K, Weiner, SJ, Sleeper, LA, Miller, ST, Embury, S, Moohr, JW, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288–294.Google Scholar

Lebensburger, JD, Miller, ST, Howard, TH, Casella, JF, Brown, RC, Lu, M, et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatric Blood & Cancer. 2012;59(4):675–678.Google Scholar

Goldberg, MF. Natural history of untreated proliferative sickle retinopathy. Archives of Ophthalmology. 1971;85(4):428–437.Google Scholar

Pegelow, CH, Colangelo, L, Steinberg, M, Wright, EC, Smith, J, Phillips, G, et al. Natural history of blood pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. The American Journal of Medicine. 1997;102(2):171–177.Google Scholar

Sarnaik, S, Slovis, TL, Corbett, DP, Emami, A, Whitten, CF. Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. The Journal of Pediatrics. 1980;96(6):1005–1008.Google Scholar

Emond, AM, Holman, R, Hayes, RJ, Serjeant, GR. Priapism and impotence in homozygous sickle cell disease. Archives of Internal Medicine. 1980;140(11):1434–1437.Google Scholar

Marouf, R, Gupta, R, Haider, MZ, Al-Wazzan, H, Adekile, AD. Avascular necrosis of the femoral head in adult Kuwaiti sickle cell disease patients. Acta Haematologica 2003;110(1):11–15.Google Scholar

Charache, S, Terrin, ML, Moore, RD, Dover, GJ, Barton, FB, Eckert, SV, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. The New England Journal of Medicine. 1995;332(20):1317–1322.Google Scholar

Vichinsky, EP, Johnson, R, Lubin, BH. Multidisciplinary approach to pain management in sickle cell disease. The American Journal of Pediatric Hematology/Oncology. 1982;4(3):328–333.Google Scholar

Hagmeyer, KO, Mauro, LS, Mauro, VF. Meperidine-related seizures associated with patient-controlled analgesia pumps. The Annals of Pharmacotherapy. 1993;27(1):29–32.Google Scholar

The Management of Sickle Cell Disease. In: USDoHaH, ed. Services. 4th edition. National Institutes of Health, Bethesda, MD; 2004:59–74.Google Scholar

Inturrisi, CE. Pharmacology of methadone and its isomers. Minerva Anestesiologica. 2005;71(7–8):435–437.Google Scholar

McCance-Katz, EF. (R)-methadone versus racemic methadone: what is best for patient care? Addiction. 2011;106(4):687–688.Google Scholar

Uprety, D, Baber, A, Foy, M. Ketamine infusion for sickle cell pain crisis refractory to opioids: a case report and review of literature. Annals of Hematology. 2014;93(5):769–771.Google Scholar

Tawfic, QA, Faris, AS, Kausalya, R. The role of a low-dose ketamine-midazolam regimen in the management of severe painful crisis in patients with sickle cell disease. Journal of Pain and Symptom Management. 2014;47(2):334–340.Google Scholar

Aygun, B, McMurray, MA, Schultz, WH, Kwiatkowski, JL, Hilliard, L, Alvarez, O, et al. Chronic transfusion practice for children with sickle cell anaemia and stroke. British Journal of haematology. 2009;145(4):524–528.Google Scholar

Enninful-Eghan, H, Moore, RH, Ichord, R, Smith-Whitley, K, Kwiatkowski, JL. Transcranial Doppler ultrasonography and prophylactic transfusion program is effective in preventing overt stroke in children with sickle cell disease. The Journal of Pediatrics. 2010;157(3):479–484.Google Scholar

Ancel, D, Amiot, X, Chaslin-Ferbus, D, Hagege, I, Garioud, A, Girot, R, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. European Journal of Gastroenterology & Hepatology. 2009;21(7):726–729.Google Scholar

Siegel, JF, Rich, MA, Brock, WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. The Journal of Urology. 1993;150(5 Pt 1):1480–1482.Google Scholar

Roy, NB et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev. 2017, https://www.ncbi.nlm.nih.gov/pubmed/28672087.CrossRef Google Scholar PubMed

Wang, WC, Ware, RE, Miller, ST, Iyer, RV, Casella, JF, Minniti, CP, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672.Google Scholar

Neumayr, LD, Aguilar, C, Earles, AN, Jergesen, HE, Haberkern, CM, Kammen, BF, et al. Physical therapy alone compared with core decompression and physical therapy for femoral head osteonecrosis in sickle cell disease. Results of a multicenter study at a mean of three years after treatment. Journal of Bone and Joint Surgery. 2006;88(12):2573–2582.Google Scholar

Platt, OS, Brambilla, DJ, Rosse, WF, Milner, PF, Castro, O, Steinberg, MH, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. The New England Journal of Medicine. 1994;330(23):1639–1644.Google Scholar

Bunn, HF. Sickle hemoglobin and other hemoglobin mutants. In: Stamatoyannopoulos, G, Nienhuis, AW, Majerus, PO, et al., eds. The Molecular Basis of Blood Disease. 2nd ed. Philadelphia: WB Saunders; 1993: __.Google Scholar

Bunn, HF, Forget, BG. Hemoglobin: Molecular, Cellular and Clinical Aspects. Philadelphia: WB Saunders; 1985.Google Scholar

Cortazzo, JA, Lichtman, AD. Methemoglobinemia: A review and recommendations for management. J Cardiothorac Vasc Anesth. 2014; 28:1043.Google Scholar

Dickerson, RE, Geis, I. Hemoglobin: Structure, Function, Evolution, and Pathology. Menlo Park, CA: Benjamin-Cummings; 1983.Google Scholar

Ho, C, ed. Hemoglobin and Oxygen Binding. New York: Elsevier Biomedical; 1982.Google Scholar

Perutz, MF. Molecular anatomy, physiology, and pathology of hemoglobin. In: Stamatoyannopoulos, G, Nienhuis, AW, Leder, P, et al., eds. The Molecular Basis of Blood Diseases. Philadelphia: WB Saunders; 1987:127.Google Scholar

Smith, RP, Olson, MV. Drug-induced methemoglobinemia. Semin Hematol. 1973; 10:253.Google Scholar

Wright, RO, Lewander, WJ, Woolf, AD. Methemoglobinemia: Etiology, pharmacology, and clinical management. Ann Emerg Med. 1999; 34:646.Google Scholar

Sokol, RJ, Booker, DJ, Stamps, R. The pathology of autoimmune haemolytic anaemia. J Clin Pathol. 1992; 45(12): 1047–1052.Google Scholar

Sachs, UJ, et al. Does a negative direct antiglobulin test exclude warm autoimmune haemolytic anaemia? A prospective study of 504 cases. Br J Haematol. 2006; 132(5): 655–656.CrossRef Google Scholar PubMed

Wheeler, CA, Calhoun, L, Blackall, DP. Warm reactive autoantibodies: clinical and serologic correlations. Am J Clin Pathol. 2004; 122(5): 680–685.Google Scholar

Vos, GH, Petz, L, Fudenberg, HH. Specificity of acquired haemolytic anaemia autoantibodies and their serological characteristics. Br J Haematol. 1970; 19(1): 57–66.Google Scholar

Garratty, G, Arndt, PA. An update on drug-induced immune hemolytic anemia. Immunohematology. 2007; 23(3): 105–119.Google Scholar

Worlledge, SM, Carstairs, KC, Dacie, JV. Autoimmune haemolytic anaemia associated with alpha-methyldopa therapy. Lancet. 1966; 2(7455): 135–139.Google Scholar

Garratty, G, Petz, LD. Drug-induced immune hemolytic anemia. Am J Med. 1975; 58(3): 398–407.Google Scholar

Mueller-Eckhardt, C, Salama, A. Drug-induced immune cytopenias: a unifying pathogenetic concept with special emphasis on the role of drug metabolites. Transfus Med Rev. 1990;4(1): 69–77.Google Scholar

Garratty, G, Arndt, PA. Positive direct antiglobulin tests and haemolytic anaemia following therapy with beta-lactamase inhibitor containing drugs may be associated with nonimmunologic adsorption of protein onto red blood cells. Br J Haematol. 1998; 100(4): 777–783.Google Scholar

Leger, RM, Garratty, G. Evaluation of methods for detecting alloantibodies underlying warm autoantibodies. Transfusion. 1999;39(1): 11–16.CrossRef Google Scholar PubMed

Lechner, K, Jäger, U. How I treat autoimmune hemolytic anemias in adults. Blood. 2010; 116(11): 1831–1838.Google Scholar

Murphy, S, LoBuglio, AF. Drug therapy of autoimmune hemolytic anemia. Semin Hematol. 1976; 13(4): 323–334.Google Scholar

Gehrs, BC, Friedberg, RC. Autoimmune hemolytic anemia. Am J Hematol. 2002; 69(4): 258–271.Google Scholar

Akpek, G, McAneny, D, Weintraub, L. Comparative response to splenectomy in Coombs-positive autoimmune hemolytic anemia with or without associated disease. Am J Hematol. 1999; 61(2): 98–102.Google Scholar

Atkinson, JP, Schreiber, AD, Frank, MM. Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. J Clin Invest. 1973; 52(6): 1509–1517.Google Scholar

Casaccia, M, et al. Laparoscopic splenectomy for hematologic diseases: a preliminary analysis performed on the Italian Registry of Laparoscopic Surgery of the Spleen (IRLSS). Surg Endosc. 2006; 20(8): 1214–1220.Google Scholar

Ikeda, M, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg. 2005; 241(2): 208–216.Google Scholar

Advisory Committee on Immunization Practices (ACIP) recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older–United States, 2013. MMWR Surveill Summ. 2013(62 Suppl 1): 1.Google Scholar

D’Arena, G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006; 81(8): 598–602.Google Scholar

Bussone, G, et al. Efficacy and safety of rituximab in adults’ warm antibody autoimmune haemolytic anemia: retrospective analysis of 27 cases. Am J Hematol. 2009; 84(3): 153–157.Google Scholar

Dierickx, D, et al. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study. J Intern Med. 2009; 266(5):484–491.Google Scholar

Narat, S, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005; 90(9):1273–1274.Google Scholar

Anderson, D, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007; 21(2 Suppl 1):S9–56.Google Scholar

Gertz, MA. Cold agglutinin disease and cryoglobulinemia. Clin Lymphoma. 2005; 5(4):290–293.Google Scholar

Bessman, JD, Banks, D. Spurious macrocytosis, a common clue to erythrocyte cold agglutinins. Am J Clin Pathol. 1980; 74(6):797–800.Google Scholar

Rosse, WF, Adams, JP. The variability of hemolysis in the cold agglutinin syndrome. Blood. 1980; 56(3):409–16.CrossRef Google Scholar PubMed

Feizi, T. Monotypic cold agglutinins in infection by mycoplasma pneumoniae. Nature. 1967; 215(5100):540–542.Google Scholar

Horwitz, CA, et al. Cold agglutinins in infectious mononucleosis and heterophil-antibody-negative mononucleosis-like syndromes. Blood. 1977; 50(2):195–202.Google Scholar

Swiecicki, PL, Hegerova, LT, Gertz, MA. Cold agglutinin disease. Blood. 2013; 122(7):1114–1121.Google Scholar

Nydegger, UE, Kazatchkine, MD, Miescher, PA. Immunopathologic and clinical features of hemolytic anemia due to cold agglutinins. Semin Hematol. 1991; 28(1):66–77.Google Scholar

Jaffe, CJ, Atkinson, JP, Frank, MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest. 1976; 58(4):942–949.Google Scholar

Mickley, H, Sorensen, PG. Immune haemolytic anaemia associated with ampicillin dependent warm antibodies and high titre cold agglutinins in a patient with Mycoplasma pneumonia. Scand J Haematol. 1984; 32(3):323–326.Google Scholar

Ulvestad, E. Paradoxical haemolysis in a patient with cold agglutinin disease. Eur J Haematol. 1998; 60(2):93–100.Google Scholar

Berentsen, S, et al. High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin disease. Blood. 2010; 116(17):3180–3184.Google Scholar

Berentsen, S, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004; 103(8):2925–2928.Google Scholar

Berentsen, S, et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica. 2006; 91(4):460–466.Google Scholar

Schollkopf, C, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006; 47(2):253–260.Google Scholar

Ghielmini, M, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol. 2005; 23(4):705–711.Google Scholar

Hoppe, B, et al. Response to intravenous immunoglobulin G in an infant with immunoglobulin A-associated autoimmune haemolytic anaemia. Vox Sang. 2004; 86(2):151–153.Google Scholar

Geurs, F, et al. Successful plasmapheresis in corticosteroid-resistant hemolysis in infectious mononucleosis: role of autoantibodies against triosephosphate isomerase. Acta Haematol. 1992; 88(2–3):142–146.Google Scholar

Berentsen, S. How I manage cold agglutinin disease. Br J Haematol. 2011; 153(3):309–317.CrossRef Google Scholar

Heddle, NM. Acute paroxysmal cold hemoglobinuria. Transfus Med Rev. 1989; 3(3):219–229.Google Scholar

Sivakumaran, M, et al. Paroxysmal cold haemoglobinuria caused by non-Hodgkin’s lymphoma. Br J Haematol. 1999; 105(1):278–279.Google Scholar

Ries, CA, et al. Paroxysmal cold hemoglobinuria: report of a case with an exceptionally high thermal range Donath-Landsteiner antibody. Blood. 1971; 38(4):491–499.Google Scholar

Rausen, AR, et al. Compatible transfusion therapy for paroxysmal cold hemoglobinuria. Pediatrics. 1975; 55(2):275–278.Google Scholar

Koppel, A, et al. Rituximab as successful therapy in a patient with refractory paroxysmal cold hemoglobinuria. Transfusion. 2007; 47(10):1902–1904.Google Scholar

Gregory, GP, et al. Failure of eculizumab to correct paroxysmal cold hemoglobinuria. Ann Hematol. 2011; 90(8):989–990.Google Scholar

Schrier, SL. Clinical Features and Diagnosis of Autoimmune Hemolytic Anemia: Warm Agglutinins. UpToDate; 2013. Retrieved April 7, 2014, from www.uptodate.com/contents/clinical-features-and-diagnosis-of-autoimmune-hemolytic-anemia-warm-agglutinins?source=search_result&search=autoimmune+hemolytic+anemia&selectedTitle=1~128.Google Scholar

Lichtman, MA, Williams, WJ. Williams hematology. 7th ed. New York: McGraw-Hill, Medical Pub. Division; 2006.Google Scholar

Kauke, T, Reininger, AJ. Images in clinical medicine. Livedo reticularis and cold agglutinins. N Engl J Med. 2007; 356(3):284.Google Scholar

Petz, LD GG. Immune Hemolytic Anemias. 2nd ed. Philadelphia: Churchill Livingstone; 2004.Google Scholar

Ahrens, N, Genth, R, Kiesewetter, H, Salama, A. Misdiagnosis in patients with diclofenac-induced hemolysis: new cases and a concise review. Am J Hematol. 2006; 81(2):128–131.Google Scholar

Ahrens, N, Genth, R, Salama, A. Belated diagnosis in three patients with rifampicin-induced immune haemolytic anaemia. Brit J Haematol. 2002; 117(2):441–443.Google Scholar

Snapper, I, Marks, D, Schwartz, L, Hollander, L. Hemolytic anemia secondary to mesantoin. Ann Intern Med. 1953; 39(3):619–623.Google Scholar

Arndt, PA, Garratty, G. The changing spectrum of drug-induced immune hemolytic anemia. Semin Hematol. 2005; 42(3):137–144.Google Scholar

Salama, A, Mueller-Eckhardt, C. The role of metabolite-specific antibodies in nomifensine-dependent immune hemolytic anemia. N Engl J Med. 1985; 313(8):469–474.Google Scholar

Garratty, G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010; 24(4–5):143–150.Google Scholar

Johnson, ST, Fueger, JT, Gottschall, JL. One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia—a new paradigm. Transfusion. 2007; 47(4):697–702.Google Scholar

Kirtland, HH, Mohler, DN, Horwitz, DA. Methyldopa inhibition of suppressor-lymphocyte function. N Engl J Med. 1980; 302(15):825–832.Google Scholar

Pierce, A, Nester, T. Pathology consultation on drug-induced hemolytic anemia. Am J Clin Pathol. 2011; 136(1):7–12.Google Scholar

Carstairs, KC, Breckenridge, A, Dollery, CT, Worlledge, S. Incidence of a positive direct Coombs test in patients on α-methyldopa. Lancet. 1966; 288(7455):133–135.Google Scholar

Spath, P, Garratty, G, Petz, L. Studies on the immune response to penicillin and cephalothin in humans: ii. immunohematologic reactions to cephalothin administration. J Immunol. 1971; 107(3):860–869.Google Scholar

Broadberry, RE, Farren, TW, Bevin, SV, Kohler, JA, Yates, S, Skidmore, I, et al. Tazobactam-induced haemolytic anaemia, possibly caused by non-immunological adsorption of IgG onto patient’s red cells. Transf Med. 2004; 14(1):53–57.Google Scholar

Arndt, PA, Leger, RM, Garratty, G. Positive direct antiglobulin tests and haemolytic anaemia following therapy with the beta-lactamase inhibitor, tazobactam, may also be associated with non-immunologic adsorption of protein onto red blood cells. Vox Sanguinis. 2003; 85(1):53.Google Scholar

Arndt, P, Garratty, G, Isaak, E, Bolger, M, Lu, Q. Positive direct and indirect antiglobulin tests associated with oxaliplatin can be due to drug antibody and/or drug-induced nonimmunologic protein adsorption. Transfusion. 2009; 49(4):711–718.Google Scholar

Arndt, PA, Leger, RM, Garratty, G. Serologic characteristics of ceftriaxone antibodies in 25 patients with drug-induced immune hemolytic anemia. Transfusion. 2012; 52(3):602–612.Google Scholar

Kapur, G, Valentini, RP, Mattoo, TK, Warrier, I, Imam, AA. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer. 2008; 50(1):139–142.Google Scholar

Garratty, G. Drug-induced immune hemolytic anemia. Hematology Am Soc Hematol Educ Program. 2009:73–79.Google Scholar

Viraraghavan, R, Chakravarty, AG, Soreth, J. Cefotetan-induced haemolytic anaemia. A review of 85 cases. Adverse Drug Reac Toxicol Rev. 2002; 21(1–2):101–107.Google Scholar

Croft, JD Jr., Swisher, SN Jr., Gilliland, BC, Bakemeier, RF, Leddy, JP, Weed, RI. Coombs’-test positivity induced by drugs. Mechanisms of immunologic reactions and red cell destruction. Ann Intern Med. 1968; 68(1):176–187.Google Scholar

Gallagher, PG. Abnormalities of the erythrocyte membrane. Pediatr Clin North Am. 2013; 60(6):1349–1362.Google Scholar

Perrotta, S, Gallagher, PG, Mohandas, N. Hereditary spherocytosis. Lancet. 2008; 372(9647):1411–1426.Google Scholar

Eber, S, Lux, SE. Hereditary spherocytosis – defects in proteins that connect the membrane skeleton to the lipid bilayer. Semi Hematol. 2004; 41(2):118–141.Google Scholar

Gallagher, PG. Update on the clinical spectrum and genetics of red blood cell membrane disorders. Curr Hematol Rep. 2004; 3(2):85–91.Google Scholar

Miraglia del Giudice, E, Francese, M, Nobili, B, et al. High frequency of de novo mutations in ankyrin gene (ANK1) in children with hereditary spherocytosis. J Pediatr. 1998; 132(1):117–120.Google Scholar

Miraglia del Giudice, E, Lombardi, C, Francese, M, et al. Frequent de novo monoallelic expression of beta-spectrin gene (SPTB) in children with hereditary spherocytosis and isolated spectrin deficiency. Br J Haematol. 1998; 101(2):251–254.Google Scholar

Mohandas, N, Gallagher, PG. Red cell membrane: past, present, and future. Blood. 2008; 112(10):3939–3948.Google Scholar

Lusher, JM, Barnhart, MI. The role of the spleen in the pathoophysiology of hereditary spherocytosis and hereditary elliptocytosis. Am J Pediatr Hematol Oncol. 1980; 2:31–39.Google Scholar

Safeukui, I, Buffet, PA, Deplaine, G, et al. Quantitative assessment of sensing and sequestration of spherocytic erythrocytes by the human spleen. Blood. 2012; 120(2):424–430.Google Scholar

Christensen, RD, Yaish, HM, Gallagher, PG. A pediatrician’s practical guide to diagnosing and treating hereditary spherocytosis in neonates. Pediatrics. 2015; 135(6):1107–1114.Google Scholar

Eber, SW, Armbrust, R, Schroter, W. Variable clinical severity of hereditary spherocytosis: relation to erythrocytic spectrin concentration, osmotic fragility, and autohemolysis. J Pediatr. 1990; 117(3):409–416.Google Scholar

Rocha, S, Costa, E, Catarino, C, et al. Erythropoietin levels in the different clinical forms of hereditary spherocytosis. Br J Haematol. 2005; 131(4):534–542.Google Scholar

Agre, P, Asimos, A, Casella, JF, McMillan, C. Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis. N Engl J Med. 1986; 315(25):1579–1583.Google Scholar

Agre, P, Casella, JF, Zinkham, WH, McMillan, C, Bennett, V. Partial deficiency of erythrocyte spectrin in hereditary spherocytosis. Nature. 1985; 314(6009):380–383.Google Scholar

Agre, P, Orringer, EP, Bennett, V. Deficient red-cell spectrin in severe, recessively inherited spherocytosis. N Engl J Med. 1982; 306(19):1155–1161.Google Scholar

Young, NS. Hematologic manifestations and diagnosis of parvovirus B19 infections. Clin Adv Hematol Oncol. 2006; 4(12):908–910.Google Scholar

Lefrere, JJ, Courouce, AM, Girot, R, Bertrand, Y, Soulier, JP. Six cases of hereditary spherocytosis revealed by human parvovirus infection. Br J Haematol. 1986; 62(4):653–658.Google Scholar

Delamore, IW, Richmond, J, Davies, SH. Megaloblastic anaemia in congenital spherocytosis. Br Med J. 1961; 1(5225):543–545.Google Scholar

Smith, J, Rahilly, M, Davidson, K. Extramedullary haematopoiesis secondary to hereditary spherocytosis. Br J Haematol. 2011; 154(5):543.Google Scholar

Rabhi, S, Benjelloune, H, Meziane, M, et al. Hereditary spherocytosis with leg ulcers healing after splenectomy. South Med J. 2011; 104(2):150–152.Google Scholar

Guarnone, R, Centenara, E, Zappa, M, Zanella, A, Barosi, G. Erythropoietin production and erythropoiesis in compensated and anaemic states of hereditary spherocytosis. Br J Haematol. 1996; 92(1):150–154.Google Scholar

Brugnara, C, Mohandas, N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes’s original 1934 classification to the third millennium. Curr Opin Hematol. 2013; 20(3):222–230.Google Scholar

Michaels, LA, Cohen, AR, Zhao, H, Raphael, RI, Manno, CS. Screening for hereditary spherocytosis by use of automated erythrocyte indexes. J Pediatr. 1997; 130(6):957–960.Google Scholar

Cynober, T, Mohandas, N, Tchernia, G. Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity. J Lab Clin Med. 1996; 128(3):259–269.Google Scholar

Bolton-Maggs, PH, Langer, JC, Iolascon, A, Tittensor, P, King, MJ, General Haematology Task Force of the British Committee for Standards in H. Guidelines for the diagnosis and management of hereditary spherocytosis–2011 update. Br J Haematol. 2012; 156(1):37–49.Google Scholar

Iolascon, A, Andolfo, I, Barcellini, W, et al. Recommendations for splenectomy in hereditary hemolytic anemias. Haematologica. 2017; 102(8):1304–1313.Google Scholar

Baird, RN, Macpherson, AI, Richmond, J. Red-blood-cell survival after splenectomy in congenital spherocytosis. Lancet. 1971; 2(7733):1060–1061.Google Scholar

Schilling, RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis – a personal view. Br J Haematol. 2009; 145(6):728–732.Google Scholar

Crary, SE, Ramaciotti, C, Buchanan, GR. Prevalence of pulmonary hypertension in hereditary spherocytosis. Am J Hematol. 2011; 86(12):E73–76.Google Scholar

Hayag-Barin, JE, Smith, RE, Tucker, FC Jr. Hereditary spherocytosis, thrombocytosis, and chronic pulmonary emboli: a case report and review of the literature. Am J Hematol. 1998; 57(1):82–84.Google Scholar

Schilling, RF, Gangnon, RE, Traver, MI. Delayed adverse vascular events after splenectomy in hereditary spherocytosis. J Thromb Haemost. 2008; 6(8):1289–1295.Google Scholar

Casale, M, Perrotta, S. Splenectomy for hereditary spherocytosis: complete, partial or not at all? Expert Rev Hematol. 2011; 4(6):627–635.Google Scholar

Schilling, RF. Risks and benefits of splenectomy versus no splenectomy for hereditary spherocytosis – a personal view. Br J Haematol. 2009; 145(6):728–732.Google Scholar

Wood, JH, Partrick, DA, Hays, T, Sauaia, A, Karrer, FM, Ziegler, MM. Contemporary pediatric splenectomy: continuing controversies. Pediatr Surg Int. 2011; 27(11):1165–1171.Google Scholar

Rescorla, FJ, Engum, SA, West, KW, Tres Scherer, LR, 3rd, Rouse, TM, Grosfeld, JL. Laparoscopic splenectomy has become the gold standard in children. Am Surg. 2002; 68(3):297–301.Google Scholar

Buesing, KL, Tracy, ET, Kiernan, C, et al. Partial splenectomy for hereditary spherocytosis: a multi-institutional review. J Pediatr Surg. 2011; 46(1):178–183.Google Scholar

Guizzetti, L. Total versus partial splenectomy in pediatric hereditary spherocytosis: A systematic review and meta-analysis. Pediatr Blood Cancer. 2016; 63(10):1713–1722.Google Scholar

Grace, RF, Mednick, RE, Neufeld, EJ. Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. Pediatr Blood Cancer. 2009; 52(7):865–867.Google Scholar

Dhermy, D, Garbarz, M, Lecomte, MC, et al. Hereditary elliptocytosis: clinical, morphological and biochemical studies of 38 cases. Nouv Rev Fr Hematol. 1986; 28(3):129–140.Google Scholar

Gallagher, PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol. 2004; 41(2):142–164.Google Scholar

Dhermy, D, Schrevel, J, Lecomte, MC. Spectrin-based skeleton in red blood cells and malaria. Curr Opin Hematol. 2007; 14(3):198–202.Google Scholar

Glele-Kakai, C, Garbarz, M, Lecomte, MC, et al. Epidemiological studies of spectrin mutations related to hereditary elliptocytosis and spectrin polymorphisms in Benin. Br J Haematol. 1996; 95(1):57–66.Google Scholar

Morrow, JS, Rimm, DL, Kennedy, SP, Cianci, CD, Sinard, JH, Weed, SA. Of membrane stability and mosaics: the spectrin cytoskeleton. In: Hoffman, J, Jamieson, J, eds. Handbook of Physiology. London: Oxford; 1997:485–540.Google Scholar

Gaetani, M, Mootien, S, Harper, S, Gallagher, PG, Speicher, DW. Structural and functional effects of hereditary hemolytic anemia-associated point mutations in the alpha spectrin tetramer site. Blood. 2008; 111(12):5712–5720.Google Scholar

Ipsaro, JJ, Harper, SL, Messick, TE, Marmorstein, R, Mondragon, A, Speicher, DW. Crystal structure and functional interpretation of the erythrocyte spectrin tetramerization domain complex. Blood. 2010; 115(23):4843–4852.Google Scholar

Coetzer, T, Lawler, J, Prchal, JT, Palek, J. Molecular determinants of clinical expression of hereditary elliptocytosis and pyropoikilocytosis. Blood. 1987; 70(3):766–772.Google Scholar

Coetzer, T, Palek, J, Lawler, J, et al. Structural and functional heterogeneity of alpha spectrin mutations involving the spectrin heterodimer self-association site: relationships to hematologic expression of homozygous hereditary elliptocytosis and hereditary pyropoikilocytosis. Blood. 1990; 75(11):2235–2244.Google Scholar

Gallagher, PG. Red cell membrane disorders. Hematology Am Soc Hematol Educ Program. 2005; 2005(1):13–18.Google Scholar

Zarkowsky, HS, Mohandas, N, Speaker, CB, Shohet, SB. A congenital haemolytic anaemia with thermal sensitivity of the erythrocyte membrane. Br J Haematol. 1975; 29(4):537–543.Google Scholar

Gallagher, PG. Disorders of red cell volume regulation. Curr Opin Hematol. 2013; 20(3):201–207.Google Scholar

Andolfo, I, Russo, R, Gambale, A, Iolascon, A. New insights on hereditary erythrocyte membrane defects. Haematologica. 2016; 101(11):1284–1294.Google Scholar

Zarychanski, R, Schulz, VP, Houston, BL, et al. Mutations in the mechanotransduction protein PIEZO1 are associated with hereditary xerocytosis. Blood. 2012; 120(9):1908–1915.Google Scholar

Bruce, LJ, Robinson, HC, Guizouarn, H, et al. Monovalent cation leaks in human red cells caused by single amino-acid substitutions in the transport domain of the band 3 chloride-bicarbonate exchanger, AE1. Nat Genet. 2005; 37(11):1258–1263.Google Scholar

Guizouarn, H, Martial, S, Gabillat, N, Borgese, F. Point mutations involved in red cell stomatocytosis convert the electroneutral anion exchanger 1 to a non-selective cation conductance. Blood. 2007; 110(6):2158–2165.Google Scholar

Murray, CJ, Rosenfeld, LC, Lim, SS, Andrews, KG, Foreman, KJ, Haring, D, Fullman, N, Naghavi, M, Lozano, R, Lopez, AD. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet. 2012; 379:413–431.Google Scholar

McDevitt, M, Xie, J, Gordeuk, V, Bucala, R. The anemia of malaria infection: role of inflammatory cytokines. Curr Hematol Rep. 2004; 3:97–106.Google Scholar

Haldar, K, Mohandas, N. Malaria, erythrocytic infection, and anemia. Hematology Am Soc Hematol Educ Program. 2009:87–93.Google Scholar

Jakeman, PH, Saul, A, Hogarth, WL, Collins, WE. Anaemia of acute malaria infections in non-immune patients primarily results from destruction of uninfected erythrocytes. Parasitology. 2004; 119:127–133.Google Scholar

Waitumbi, J, Opollo, M, Muga, R, Misore, A, Stoute, J. Red cell surface changes and erythrophagocytosis in children with severe Plasmodium falciparum anemia. Blood. 2000;95:1481–1486.Google Scholar

Stoute, JA, Odindo, AO, Owuor, BO, Mibei, EK, Opollo, MO, Waitumbi, JN. Loss of red blood cell-complement regulatory proteins and increased levels of circulating immune complexes are associated with severe malarial anemia. J Infect Dis. 2003; 187:522–525.Google Scholar

Weatherall, D, Kwiatkowski, D, Roberts, D. Hematologic manifestations of systemic disease in children of the developing world. In: Orkin, SH, Ginsburg, D, Nathan, DG, Look, TA, Fisher, DE, Lux, SE, editors, Nathan and Oski?s Hematology and Oncology of Infancy and Childhood, 8th edition, Amsterdam: Elsevier; 2008.Google Scholar

Wickramasinghe, S, Abdalla, S. Blood and bone marrow changes in malaria. Baillieres Best Pract Res Clin Haematol. 2003; 13:277–299.Google Scholar

Abdalla, SH. Hematopoiesis in human malaria. Blood Cells. 1990; 16:401–416.Google Scholar

Srichaikul, T, Wasanasomsithi, M, Poshyachinda, V, Panikbutr, N, Rabieb, T. Ferrokinetic studies and erythropoiesis in malaria. Arch Intern Med. 1969; 124:623–628.Google Scholar

Biemba, G, Gordeuk, V, Thuma, P, Mabeza, GF, Weiss, G. Prolonged macrophage activation and persistent anemia in children with complicated malaria. Trop Med Int Health. 1998; 3:60–65.Google Scholar

Das, B, Nanda, N, Rath, P, Satapathy, R, Das, D. Anaemia in acute Plasmodium falciparum malaria in children from the Orissa state, India. Ann Trop Med Parasitol. 1999; 93:109–118.Google Scholar

Lamikanra, AA, Theron, M, Kooij, TW, Roberts, DJ. Hemozoin (malarial pigment) directly promotes apoptosis of erythroid precursors. PLoS One. 2009;4:e8446.Google Scholar

Kremsner, PG, Valim, C, Missinou, MA, Olola, C, Krishna, S, Issifou, S, Kombila, M, Bwanaisa, L, Mithwani, S, Newton, CR, Agbenyega, T, Pnder, M, Bojang, K, Wypij, D, Taylor, T. Prognostic value of circulating pigmented cells in African children with malaria. J Infect Dis. 2009; 199:142–150.Google Scholar

Stevenson, MM, Riley, EM. Innate Immunity to Malaria. Nat Revs Immunol. 2004; 4:169–180.Google Scholar

Yap, GS, Stevenson, MM. Inhibition of in vitro erythropoiesis by soluble mediators during Plasmodium chabaudi AS malaria: lack of a major role for interleukin-1, tumor necrosis factor-α, and γ-interferon. Infect Immun. 1994; 62:357–362.Google Scholar

Kwiatkowski, D, Cannon, JG, Manogue, KR, Cerami, A, Dinarello, CA, Greenwood, BM. Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol. 1989; 77:361–366.Google Scholar

Thuma, PE, van Dijk, J, Bucala, R, Debebe, Z, Nekhai, S, Kuddo, T, Nouraie, M, Weiss, G, Gordeuk, VR. Distinct clinical and immunologic profiles in severe malarial anemia and cerebral malaria in Zambia. J Infect Dis. 2011; 203:211–219.Google Scholar

Looareesuwan, S, Merry, AH, Phillips, RE, Pleehachinda, R, Wattanagoon, Y, Ho, M, Charoenlarp, P, Warrell, DA, Weatherall, DJ. Reduced erythrocyte survival following clearance of malarial parasitaemia in Thai patients. Br J Haematol. 1987; 67:473–478.Google Scholar

Nicolas, G, Chauvet, C, Viatte, L, Danan, JL, Bigard, X, Devaux, I, Beaumont, C, Kahn, A, Vaulont, S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002; 110:1037–1044.Google Scholar

Burté, F, Brown, BJ, Orimadegun, AE, Ajetunmobi, WA, Afolabi, NK, Akinkunmi, F, Kowobari, O, Omokhodion, S, Osinusi, K, Akinbami, FO, Shokunbi, WA, Sodeinde, O, Fernandez-Reyes, D. Circulatory hepcidin is associated with the anti-inflammatory response but not with iron or anemic status in childhood malaria. Blood. 2013; 121:3016–3022.Google Scholar

Burchard, G, Radloff, P, Philipps, J, Nkeyi, M, Knobloch, J, Kremsner, P. Increased erythropoietin production in children with severe malarial anemia. Am J Trop Med Hyg. 1995; 53:547–551.Google Scholar

Burgmann, H, Looareesuwan, S, Kapiotis, S, Viravan, C, Vanijanonta, S, Hollenstein, U, Wiesinger, E, Presterl, E, Winkler, S, Graninger, W. Serum levels of erythropoietin in acute Plasmodium falciparum malaria. Am J Trop Med Hyg. 1996; 54:280–283.Google Scholar

Griffith, JW, Sun, T, McIntosh, MT, Bucala, R. Pure hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid. J Immunol. 2009; 183:5208–5220.Google Scholar

Dodoo, D, Omer, FM, Todd, J, Akanmori, BD, Koram, KA, Riley, EM. Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis. 2002; 185:971–979.Google Scholar

Mohan, K, Stevenson, MM. Interleukin-12 corrects severe anemia during blood-stage Plasmodium chabaudi AS in susceptible A/J mice. Exp Hematol. 1998; 26:45–52.Google Scholar

Mcguire, W, Knight, JC, Hill, AVS, Allsopp, CEM, Greenwood, BM, Kwiatkowski, D. Severe malarial anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J Infect Dis. 1999; 179:287–290.Google Scholar

McDevitt, MA, Xie, J, Shanmugasundaram, G, Griffith, J, Liu, A, McDonald, C, Thuma, P, Gordeuk, VR, Metz, CN, Mitchell, R, Keefer, J, David, J, Leng, L, Bucala, R. A critical role for the host mediator macrophage migration inhibitory factor in the pathogenesis of malarial anemia. J Exp Med. 2006; 203:1185–1196.Google Scholar

Zhong, XB, Leng, L, Beitin, A, Chen, R, McDonald, C, Hsiao, B, Jenison, RD, Kang, I, Park, SH, Lee, A, Gregersen, P, Thuma, P, Bray-Ward, P, Ward, DC, Bucala, R. Simultaneous detection of microsatellite repeats and SNPs in the macrophage migration inhibitory factor (MIF) gene by thin-film biosensor chips and application to rural field studies. Nucleic Acids Res. 2005;33:121–129.Google Scholar

Awandare, GA, Martinson, JJ, Were, T, Ouma, C, Davenport, GC, Ong’echa, JM, Wang, WK, Leng, L, Ferrell, RE, Bucala, R, Perkins, DJ. MIF promoter polymorphisms and susceptibility to severe malarial anemia. J Infect Dis. 2009; 15:629–637.Google Scholar

Jha, AN, Sundaradival, P, Pati, SS, Patra, PK, Thandaraj, K. Variations in ncRNA gene LOC284889 and MIF-794CATT repeats are associated with malaria susceptibility in Indian populations. Malar J. 2013;12:345–353.Google Scholar

Published Reports of Delayed Hemolytic Anemia After Treatment with Artesunate for Severe Malaria – Worldwide, 2010–2012. Morb Mortal Wkly Rep. 2013;62(1):5–8.Google Scholar

Akinosoglou, KS, Solomou, EE, Gogos, CA. Malaria: a haematological disease. Hematology. 2012; 17:106–114.Google Scholar

English, M, Ahmed, M, Ngando, C, Berkley, J, Ross, A. Blood transfusion for severe anaemia in children in a Kenyan hospital. Lancet. 2002; 359:494–495.Google Scholar

van Genderen, PJ, Hesselink, DA, Bezemer, JM, Wismans, PJ, Overbosch, D. efficacy and safety of exchange transfusion as adjunct therapy for severe Plasmodium falciparum malaria in nonimmune travelers: a 10 year single-center experience with a standardized treatments protocol. Transfusion. 2010; 50:787–794.Google Scholar

Nieuwenhuis, JA, Meertens, JH, Zijlstra, JG, Ligtenberg, JJ, Tulleken, JE, van der Werf, TS. Automated erythrocytapheresis in severe falciparum malaria: a critical appraisal. Acta Trop. 2006; 98:201–206.Google Scholar

Zini, G, d’Onofrio, G, Briggs, C, Erber, W, Jou, JM, Lee, SH, et al. ICSH recommendations for identification, diagnostic value, and quantitation of schistocytes. Int J Labor Hematol. 2012; 34(2):107–116.Google Scholar

Furlan, M, Robles, R, Galbusera, M, Remuzzi, G, Kyrle, PA, Brenner, B, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998; 339(22):1578–1584.Google Scholar

Kremer Hovinga, JA, Vesely, SK, Terrell, DR, Lammle, B, George, JN. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010; 115(8):1500–1511.Google Scholar

Coppo, P, Bengoufa, D, Veyradier, A, Wolf, M, Bussel, A, Millot, GA, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore). 2004; 83(4):233–244.Google Scholar

Terrell, DR, Vesely, SK, Kremer Hovinga, JA, Lammle, B, George, JN. Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010; 85(11):844–847.Google Scholar

Terrell, DR, Williams, LA, Vesely, SK, Lammle, B, Hovinga, JA, George, JN. The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005; 3(7):1432–1436.Google Scholar

Miller, DP, Kaye, JA, Shea, K, Ziyadeh, N, Cali, C, Black, C, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. Epidemiology. 2004; 15(2):208–215.Google Scholar

Miyata, T, Kokame, K, Matsumoto, M, Fujimura, Y. ADAMTS13 activity and genetic mutations in Japan. Hamostaseologie. 2013; 33(2):131–137.Google Scholar

Tarr, PI, Gordon, CA, Chandler, WL. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 2005; 365(9464):1073–1086.Google Scholar

Frank, C, Werber, D, Cramer, JP, Askar, M, Faber, M, an der Heiden, M, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med. 2011; 365(19):1771–1780.Google Scholar

Lemaire, M, Fremeaux-Bacchi, V, Schaefer, F, Choi, M, Tang, WH, Le Quintrec, M, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013; 45(5):531–536.Google Scholar

Taylor, CM, Machin, S, Wigmore, SJ, Goodship, TH, working party from the Renal Association tBCfSiH, the British Transplantation S. Clinical practice guidelines for the management of atypical haemolytic uraemic syndrome in the United Kingdom. Br J Haematol. 2010; 148(1):37–47.Google Scholar

Lotta, LA, Garagiola, I, Palla, R, Cairo, A, Peyvandi, F. ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat. 2010; 31(1):11–19.Google Scholar

Inward, CD, Howie, AJ, Fitzpatrick, MM, Rafaat, F, Milford, DV, Taylor, CM. Renal histopathology in fatal cases of diarrhoea-associated haemolytic uraemic syndrome. British Association for Paediatric Nephrology. Pediatr Nephrol. 1997; 11(5):556–559.Google Scholar

Taylor, CM, Chua, C, Howie, AJ, Risdon, RA, British Association for Paediatric N. Clinico-pathological findings in diarrhoea-negative haemolytic uraemic syndrome. Pediatr Nephrol. 2004; 19(4):419–425.Google Scholar

Scully, M, Hunt, BJ, Benjamin, S, Liesner, R, Rose, P, Peyvandi, F, et al. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012; 158(3):323–335.Google Scholar

Loirat, C, Fremeaux-Bacchi, V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis. 2011; 6:60.Google Scholar

Noris, M, Caprioli, J, Bresin, E, Mossali, C, Pianetti, G, Gamba, S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010; 5(10):1844–1859.Google Scholar

Rieger, M, Mannucci, PM, Kremer Hovinga, JA, Herzog, A, Gerstenbauer, G, Konetschny, C, et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood. 2005; 106(4):1262–1267.Google Scholar

Schwartz, J, Winters, JL, Padmanabhan, A, Balogun, RA, Delaney, M, Linenberger, ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013; 28(3):145–284.Google Scholar

O’Brien, KL, Price, TH, Howell, C, Delaney, M. The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura. J Clin Apher. 2013; 28(6):416–421.Google Scholar

Zhan, H, Streiff, MB, King, KE, Segal, JB. Thrombotic thrombocytopenic purpura at the Johns Hopkins Hospital from 1992 to 2008: clinical outcomes and risk factors for relapse. Transfusion. 2010; 50(4):868–874.Google Scholar

Westwood, JP, Webster, H, McGuckin, S, McDonald, V, Machin, SJ, Scully, M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013; 11(3):481–490.Google Scholar

Hie, M, Gay, J, Galicier, L, Provot, F, Presne, C, Poullin, P, et al. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura: experience of the French Thrombotic Microangiopathies Reference Center. Blood. 2014; 124(2):204–210.Google Scholar

Bharat, A, Xie, F, Baddley, JW, Beukelman, T, Chen, L, Calabrese, L, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthr Care Res. 2012; 64(4):612–615.Google Scholar

Lunel-Fabiani, F, Masson, C, Ducancelle, A. Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation. Joint, bone, spine: revue du rhumatisme. Joint Bone Spine. 2014; 81(6):478–484.Google Scholar

Shortt, J, Oh, DH, Opat, SS. ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med. 2013; 368(1):90–92.Google Scholar

Ahmad, HN, Thomas-Dewing, RR, Hunt, BJ. Mycophenolate mofetil in a case of relapsed, refractory thrombotic thrombocytopenic purpura. Eur J Haematol. 2007; 78(5):449–452.Google Scholar

Li, GW, Rambally, S, Kamboj, J, Reilly, S, Moake, JL, Udden, MM, et al. Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report. Transfusion. 2014; 54(5):1221–1224.Google Scholar

Cataland, SR, Peyvandi, F, Mannucci, PM, Lammle, B, Kremer Hovinga, JA, Machin, SJ, et al. Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura. Am J Hematol. 2012; 87(4):430–432.Google Scholar

Callewaert, F, Roodt, J, Ulrichts, H, Stohr, T, van Rensburg, WJ, Lamprecht, S, et al. Evaluation of efficacy and safety of the anti-VWF Nanobody ALX-0681 in a preclinical baboon model of acquired thrombotic thrombocytopenic purpura. Blood. 2012; 120(17):3603–3610.Google Scholar

Scully, M, Thomas, M, Underwood, M, Watson, H, Langley, K, Camilleri, RS, et al. Congenital and acquired thrombotic thrombocytopenic purpura and pregnancy: presentation, management and outcome of subsequent pregnancies. Blood. 2014; 124(2):211–219.Google Scholar

Menne, J, Nitschke, M, Stingele, R, Abu-Tair, M, Beneke, J, Bramstedt, J, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ. 2012; 345:e4565.Google Scholar

Braune, SA, Wichmann, D, von Heinz, MC, Nierhaus, A, Becker, H, Meyer, TN, et al. Clinical features of critically ill patients with Shiga toxin-induced hemolytic uremic syndrome. Crit Care Med. 2013; 41(7):1702–1710.Google Scholar

Wong, CS, Mooney, JC, Brandt, JR, Staples, AO, Jelacic, S, Boster, DR, et al. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis. 2012; 55(1):33–41.Google Scholar

Legendre, CM, Licht, C, Muus, P, Greenbaum, LA, Babu, S, Bedrosian, C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013; 368(23):2169–2181.Google Scholar

Fremeaux-Bacchi, V, Fakhouri, F, Garnier, A, Bienaime, F, Dragon-Durey, MA, Ngo, S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013; 8(4):554–562.Google Scholar

Noris, M, Remuzzi, G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens. 2013; 22(6):704–712.Google Scholar

Rodgers, , et al. Hemolytic anemia following prosthetic valve replacement. Circulation. 1969; 39:155–161.CrossRef Google Scholar PubMed

Eyster, E, et al. Chronic intravascular hemolysis after aortic valve replacement. Circulation. 1971; 44:657–665.Google Scholar

Skoularigis, J, et al. Frequency and severity of intravascular hemolysis after left-sided cardiac valve replacement with Medtronic Hall and St. Jude Medical prostheses, and influence of prosthetic type, position, size and number. Am J Cardiol. 1993; 71:587–591 .Google Scholar

Skoularigis, J, et al. Frequency and severity of intravascular hemolysis after left-sided cardiac valve replacement with Medtronic Hall and St. Jude Medical prostheses, and influence of prosthetic type, position, size and number. Am J Cardiol. 1993; 71:587–591.Google Scholar

Chang, H, et al. Chronic intravascular hemolysis after valvular surgery. J. Formos Med Assoc. 1990; 89:880.Google Scholar

Shapira, Y, et al. Hemolysis associated with prosthetic heart valves. Cardiology in Review. 2009; 17:121–124.Google Scholar

Mecozzi, G, et al. Intravascular hemolysis in patients with new-generation prosthetic heart valves: a prospective study. J Thorac Cardiovasc Surg. 2002; 123:550–556.Google Scholar

Shapira, Y, et al. Hemolysis associated with prosthetic heart valves. Cardiol Rev. 2009; 17:121–124.Google Scholar

Demirsoy, E, et al. Hemolysis after mitral valve repair: a report of five cases and literature review. J Heart Valve Dis. 2008; 17:24–30.Google Scholar

Nevaril, CG, et al. Erythrocyte damage and destruction induced by shearing stress. J Lab Clin Med. 1968; 71:784.Google Scholar

Linde, T, et al. Aortic root compliance influences hemolysis in mechanical heart valve prostheses: an in-vitro study. Int J Artif Organs. 2012; 35:495–502.Google Scholar

Sears, DA, et al. Intravascular hemolysis due to intracardiac prosthetic devices: diurnal variations related to activity. Am J Med. 1965; 39:341–354.Google Scholar

Mecozzi, G, et al. Intravascular hemolysis in patients with new-generation prosthetic heart valves: a prospective study. J Thorac Cardiovasc Surg. 2002; 123:550–556.Google Scholar

Shapira, Y, et al. Hemolysis associated with prosthetic heart valves. Cardiol Rev. 2009; 17:121–124 .Google Scholar

Maraj, R, et al. Evaluation of hemolysis in patients with prosthetic heart valves. Clin Cardiol 1998; 21:387–392.Google Scholar

Shapira, Y, et al. Hemolysis associated with prosthetic heart valves. Cardiol Rev. 2009; 17:121–124.Google Scholar

Rodgers, , et al. Hemolytic anemia following prosthetic valve replacement. Circulation. 1969; 39:155–161.Google Scholar

Shapira, Y, et al. Hemolysis associated with prosthetic heart valves. Cardiol Rev. 2009; 17:121–124.Google Scholar

Shapira, Y, et al. Erythropoietin can obviate the need for repeated heart valve replacement in high-risk patients with severe mechanical hemolytic anemia: case reports and literature review. J Heart Valve Dis. 2001; 10:431–435.Google Scholar

Golbasi, I, et al. The effect of pentoxifylline on haemolysis in patients with double cardiac prosthetic valves. Acta Cardiol. 2003; 58:379–383.Google Scholar

Fleischer, R. Uber eine neue Form von Hämoglobinurie beim Menschen. Klin Wochenschr. 1881; 18:691.Google Scholar

Davidson, RJL. Exertional hemoglobinuria: a report on three cases with studies on the haemolytic mechanism. J Clin Pathol. 1964; 17:536–540.Google Scholar

Gilligan, DR, et al. March hemoglobinuria in a woman. N Engl J Med. 1950; 243:944–948.Google Scholar

Streeton, JA. Traumatic haemoglobinuria caused by karate exercises. Lancet. 1967; 2(7508):191–192.Google Scholar

Schwartz, KA. March hemoglobinuria: report of a case after basketball and congo drum playing. Ohio State Med J. 1973; 69:448–49.Google Scholar

Ham, TH, et al. Studies on the destruction of red blood cells. Blood. 1948; 3:373–403.Google Scholar

Endoh, Y, et al. Causes and time course of acute hemolysis after burn injury in the rat. J Burn Care Rehab. 1992; 13:203–209.Google Scholar

Ham, TH, et al. Studies on the destruction of red blood cells. Blood. 1948; 3:373–403.Google Scholar

Endoh, Y, et al. Causes and time course of acute hemolysis after burn injury in the rat. J Burn Care Rehab. 1992; 13:203–209.Google Scholar

Loebl, EC, et al. The mechanism of erythrocyte destruction in the early post-burn period. Ann Surg. 1973; 178:681–686.Google Scholar

Hatherill, JR, et al. Thermal injury, intravascular hemolysis and toxic oxygen products. J Clin Invest. 1986; 78:629–636.Google Scholar

Wilson, RJM, et al. Invasion and growth of Plasmodium falciparum in different types of human erythrocyte. Bull WHO. 1977; 55:179–185.Google Scholar

Weatherall, DJ, et al. Malaria and the red cell. Hematology(ASH Education Program). 2002; 35:35–57.Google Scholar

Yuthavong, Y, et al. The relationship of phosphorylation of membrane proteins with osmotic fragility and filterability of Plasmodium berghei-infected mouse erythrocytes. Biochim Biophys Acta. 1987; 929:278–287.Google Scholar

George, JN, et al. Erythrocytic abnormalities in experimental malaria. 1967; 124:1086–1090.Google Scholar

Overman, RR. Reversible cellular permeability alterations in disease. In vivo studies on sodium, potassium, and chloride concentrations in erythrocytes of the malarious monkey. 1948; 152:113–121.Google Scholar

www.cdc.gov/parasites/babesiosis/health_professionals/index.html#tx.Google Scholar

Ricketts, WE. Bartonella bacilliformis anemia (Oroya fever). A study of thirty cases. Blood. 1948; 3:1025–1049.Google Scholar

Xu, YH, et al. Purification of deformin, an extracellular protein synthesized by Bartonella bacilliformis which causes deformation of erythrocyte membranes. Biochim Biophys Acta. 1995; 1234:173–183.Google Scholar

Reynafarje, C, et al. The hemolytic anemia of human bartonellosis. Blood. 1961; 17:562–578.Google Scholar

Van Bunderen, CC, et al. Clostridium perfringens septicaemia with massive intravascular haemolysis: a case report and review of the literature. Neth J Med. 2010; 68:343–346.Google Scholar

Terebelo, H, et al. Implication of plasma free hemoglobin in massive clostridial hemolysis. JAMA. 1982 248:2028–2029.Google Scholar

Bätge, B, et al. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med. 1992; 18:488–490.Google Scholar

Paulino, C, et al. Clostridium perfringens sepsis with massive intravascular haemolysis: a rare presentation. J Med Cases. 2012; 3:207–210.Google Scholar

Bätge, B, et al. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med. 1992; 18:488–490.Google Scholar

Klein, RL, et al. T-cryptantigen exposure in neonatal necrotizing enterocolitis. J. Pediatric Surg. 1986; 21:1155–1158.Google Scholar

Placzek, MM, et al. T activation haemolysis and death after blood transfusion. Arch Dis Child. 1987; 62:743–744.Google Scholar

McPharlane, RG, et al. Hemolysis and production of opalescence in serum and lecitho-vitillin by a toxin of Clostridium welchii. J Pathol Bacteriol. 1941; 522:99–103.Google Scholar

Bennett, JM, et al. Spherocytic hemolytic anemia and acute cholecystitis caused by Clostridium welchii. N Engl J Med. 1968; 268:1070–1072.Google Scholar

Hübel, W, et al. Investigation of the pathogenesis of massive hemolysis in a case of Clostridium perfringens septicemia. Ann Hematol. 1993; 67:145–147.Google Scholar

Bätge, B, et al. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med. 1992; 18:488–490.Google Scholar

Paulino, C, et al. Clostridium Perfringens sepsis with massive intravascular haemolysis: a rare presentation. J Med Cases. 2012; 3:207–210.Google Scholar

Bätge, B, et al. Clostridial sepsis with massive intravascular hemolysis: rapid diagnosis and successful treatment. Intensive Care Med. 1992; 18:488–490.Google Scholar

Fairbanks, VF, et al. Copper sulfate-induced hemolytic anemia. Arch Intern Med. 1967; 120:428–432.Google Scholar

Robitaille, GA, et al. Hemolytic anemia in Wilson’s Disease. JAMA. 1977; 237:2402–2403.Google Scholar

Valsami, S, et al. Acute copper sulphate poisoning: a forgotten cause of severe intravascular haemolysis. BJH. 2011; 156:294.Google Scholar

Fairbanks, VF, et al. Copper sulfate-induced hemolytic anemia. Arch Intern Med. 1967; 120:428–432.Google Scholar

Boulard, M, et al. The effect of copper on red cell enzyme activities. J Clin Invest. 1972; 51:459–461.Google Scholar

Robitaille, GA, et al. Hemolytic anemia in Wilson’s Disease. JAMA. 1977; 237:2402–2403.Google Scholar

Kiss, JE, et al. Effective removal of copper by plasma exchange in fulminant Wilson’s disease. Transfusion. 1998; 38:327–331.Google Scholar

Asfaha, S, et al. Plasmapheresis for hemolytic crisis and impending acute liver failure in Wilson disease. J Clin Apher. 2007; 22:295–298.Google Scholar

Matsumura, K, et al. Plasma exchange for hemolytic crisis in Wilson disease. Ann of Int Med. 1999; 131:866.Google Scholar

Vallee, BL, et al. Biochemical effects of mercury, cadmium, and lead. Ann Rev Biochem. 1972; 41:91–128.Google Scholar

Champe, PC, Harvey, RA, eds. Biochemistry, 4th ed. Baltimore: Lippincott Williams and Wilkins; 2008:279.Google Scholar

Lachant, NA, et al. Inhibition of the pentose phosphate shunt by lead: a potential mechanism of hemolysis in lead poisoning. Blood. 1984; 63:518–524.Google Scholar

Osband, M, et al. The hemolytic effect of lead on glucose-6-phosphate dehydrogenase deficient erythrocytes. Ped Res. 1981; 15:583.Google Scholar

Aly, MH, et al. Hemolytic anemia associated with lead poisoning from shotgun pellets and the response to Succimer treatment. Am J Hematol. 1993; 44:280–283.Google Scholar

Gelfand, EW, et al. Intravenous immune globulin in autoimmune and inflammatory diseases. NEJM. 2012; 367:2015–2025.Google Scholar

Simon, TL, et al. eds. Rossi’s Principles of Transfusion Medicine. Oxford: Blackwell Publishing, Ltd; 2009:262.Google Scholar

Kahwaji, J, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol. 2009; 4:1993–1997.Google Scholar

Pintova, S, et al. IVIG—A hemolytic culprit. NEJM. 2012; 367:974–976.Google Scholar

Thomas, MJ, et al. Hemolysis after high-dose intravenous Ig. Blood. 1993; 82:3789.Google Scholar

Pintova, S, et al. IVIG—A hemolytic culprit. NEJM. 2012; 367:974–976.Google Scholar

Crosby, WH. Normal functions of the spleen relative to red blood cells: a review. Blood. 1959; 14:399–408.Google Scholar

Cooper, RA, et al. An analysis of lipoproteins, bile acids, and red cell membranes associated with target cells and spur cells in patients with liver disease. J Clin Invest. 1972; 51:3182.Google Scholar

Morse, EE. Mechanisms of hemolysis in liver disease. Ann Clin Lab Sci. 1990; 20:169–174.Google Scholar

Cooper, RA. Anemia with spur cells: a red cell defect acquired in serum and modified in the circulation. J Clin Invest. 1969; 48:1820–1831.Google Scholar

Cooper, RA, et al. Role of the spleen in membrane conditioning and hemolysis of spur cells in liver disease. NEJM. 1974; 290:1279–1284.Google Scholar

Morse, EE. Mechanisms of hemolysis in liver disease. Ann Clin Lab Sci. 1990; 20:169–174.Google Scholar

Hilgard, P, et al. Asialoglycoprotein receptor facilitates hemolysis in patients with alcoholic liver cirrhosis. Hepatology. 2004; 39:1398–1407.Google Scholar

Ricard, MP. Spur cell hemolytic anemia of severe liver disease. Haematologica. 84:654 1999.Google Scholar

Young, NS, Kaufman, DW. The epidemiology of acquired aplastic anemia. Haematologica. 2008; 93(4):489–492.Google Scholar

Zaimoku, Y, Takamatsu, H, Hosomichi, K, Ozawa, T, Nakagawa, N, Imi, T, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017; 129(21):2908–2916.Google Scholar

Babushok, DV, Duke, JL, Xie, HM, Stanley, N, Atienza, J, Perdigones, N, et al. Somatic HLA mutations expose the role of class I-mediated autoimmunity in aplastic anemia and its clonal complications. Blood Adv. 2017; 1:1900–1910.Google Scholar

Nakao, S, Takamatsu, H, Chuhjo, T, Ueda, M, Shiobara, S, Matsuda, T, et al. Identification of a specific HLA class II haplotype strongly associated with susceptibility to cyclosporine-dependent aplastic anemia. Blood. 1994; 84(12):4257–4261.Google Scholar

Young, NS, Calado, RT, Scheinberg, P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006; 108(8):2509–2519.Google Scholar

Ehrlich, P. Uber einen Fall von Anamie mit Bemerkungen uber regenerative Veranderungen des Knochenmarks. Charite-Annalen. 1888; 13:300.Google Scholar

Pegg, DE, Fleming, WJ, Compston, N. A case of aplastic anaemia treated by isologous bone marrow infusion. Postgrad Med J. 1964; 40:213–216.Google Scholar

Thomas, ED, Storb, R, Giblett, ER, Longpre, B, Weiden, PL, Fefer, A, et al. Recovery from aplastic anemia following attempted marrow transplantation. Exp Hematol. 1976; 4(2):97–102.Google Scholar

Ascensao, J, Pahwa, R, Kagan, W, Hansen, J, Moore, M, Good, R. Aplastic anaemia: evidence for an immunological mechanism. Lancet. 1976; 1(7961):669–671.Google Scholar

Dunn, DE, Tanawattanacharoen, P, Boccuni, P, Nagakura, S, Green, SW, Kirby, MR, et al. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes. Ann Intern Med. 1999; 131(6):401–408.Google Scholar

Katagiri, T, Sato-Otsubo, A, Kashiwase, K, Morishima, S, Sato, Y, Mori, Y, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011; 118(25):6601–9660.Google Scholar

Socie, G, Rosenfeld, S, Frickhofen, N, Gluckman, E, Tichelli, A. Late clonal diseases of treated aplastic anemia. Semin Hematol. 2000; 37(1):91–101.Google Scholar

Gupta, V, Eapen, M, Brazauskas, R, Carreras, J, Aljurf, M, Gale, RP, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010; 95(12):2119–2125.Google Scholar

Locasciulli, A, Oneto, R, Bacigalupo, A, Socie, G, Korthof, E, Bekassy, A, et al. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007; 92(1):11–18.Google Scholar

Storb, R, Etzioni, R, Anasetti, C, Appelbaum, FR, Buckner, CD, Bensinger, W, et al. Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood. 1994; 84(3):941–949.Google Scholar

Maury, S, Bacigalupo, A, Anderlini, P, Aljurf, M, Marsh, J, Socie, G, et al. Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen. Haematologica. 2009; 94(9):1312–1315.Google Scholar

Bacigalupo, A, Socie, G, Schrezenmeier, H, Tichelli, A, Locasciulli, A, Fuehrer, M, et al. Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. Haematologica. 2012; 97(8):1142–1148.Google Scholar

Bacigalupo, A, Marsh, JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18–40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant. 2013; 48(2):198–200.Google Scholar

DeZern, AE, Zahurak, M, Symons, H, Cooke, K, Jones, RJ, Brodsky, RA. Alternative donor transplantation with high-dose post-transplantation cyclophosphamide for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2017; 23(3):498–504.Google Scholar

Esteves, I, Bonfim, C, Pasquini, R, Funke, V, Pereira, NF, Rocha, V, et al. Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study. Bone Marrow Transplant. 2015; 50(5):685–689.Google Scholar

Frickhofen, N, Kaltwasser, JP, Schrezenmeier, H, Raghavachar, A, Vogt, HG, Herrmann, F, et al. Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med. 1991; 324(19):1297–1304.Google Scholar

Scheinberg, P, Nunez, O, Weinstein, B, Biancotto, A, Wu, CO, Young, NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011; 365(5):430–438.Google Scholar

Hochsmann, B, Moicean, A, Risitano, A, Ljungman, P, Schrezenmeier, H. Supportive care in severe and very severe aplastic anemia. Bone Marrow Transplant. 2013; 48(2):168–73.Google Scholar

Young, NS, Bacigalupo, A, Marsh, JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010; 16(1 Suppl):S119–125.Google Scholar

Saracco, P, Quarello, P, Iori, AP, Zecca, M, Longoni, D, Svahn, J, et al. Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up. Br J Haematol. 2008; 140(2):197–205.Google Scholar

Townsley, DM, Scheinberg, P, Winkler, T, Desmond, R, Dumitriu, B, Rios, O, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017; 376(16):1540–1550.Google Scholar

Fureder, W, Valent, P. Treatment of refractory or relapsed acquired aplastic anemia: review of established and experimental approaches. Leuk Lymphoma. 2011; 52(8):1435–1445.Google Scholar

Shahani, S, Braga-Basaria, M, Maggio, M, Basaria, S. Androgens and erythropoiesis: past and present. J Endocrinol Invest. 2009; 32(8):704–716.Google Scholar

Olnes, MJ, Scheinberg, P, Calvo, KR, Desmond, R, Tang, Y, Dumitriu, B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012; 367(1):11–19.Google Scholar

Desmond, R, Townsley, DM, Dumitriu, B, Olnes, MJ, Scheinberg, P, Bevans, M, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood. 2014; 123(12):1818–1825.Google Scholar

Sawada, K, Hirokawa, M, Fujishima, N. Diagnosis and management of acquired pure red cell aplasia. Hematol Oncol Clin North Am. 2009; 23(2):249–259.Google Scholar

Brown, KE, Anderson, SM, Young, NS. Erythrocyte P antigen: cellular receptor for B19 parvovirus. Science. 1993; 262(5130):114–117.Google Scholar

Macdougall, IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant. 2005; 20 Suppl 4:iv9–15.Google Scholar

Bolan, CD, Leitman, SF, Griffith, LM, Wesley, RA, Procter, JL, Stroncek, DF, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001; 98(6):1687–1694.Google Scholar

Kurtzman, G, Frickhofen, N, Kimball, J, Jenkins, DW, Nienhuis, AW, Young, NS. Pure red-cell aplasia of 10 years’ duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med. 1989; 321(8):519–523.Google Scholar

Sawada, K, Fujishima, N, Hirokawa, M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008; 142(4):505–514.Google Scholar

Macdougall, IC, Rossert, J, Casadevall, N, Stead, RB, Duliege, AM, Froissart, M, et al. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009; 361(19):1848–1855.Google Scholar

Clark, DA, Dessypris, EN, Krantz, SB. Studies on pure red cell aplasia. XI. Results of immunosuppressive treatment of 37 patients. Blood. 1984; 63(2):277–286.Google Scholar

Sawada, K, Hirokawa, M, Fujishima, N, Teramura, M, Bessho, M, Dan, K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007; 92(8):1021–1028.Google Scholar

Risitano, AM, Selleri, C, Serio, B, Torelli, GF, Kulagin, A, Maury, S, et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol. 2010; 148(5):791–796.Google Scholar

Hillmen, P, Lewis, SM, Bessler, M, Luzzatto, L, Dacie, JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995; 333:1253–1258.Google Scholar

Socie, G, Mary, JY, de Gramont, A, Rio, B, Leporrier, M, Rose, C, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996 Aug 31; 348(9027):573–577.Google Scholar

Moyo, VM, Mukhina, GL, Garrett, ES, Brodsky, RA. Natural history of paroxysmal nocturnal hemoglobinuria using modern diagnostic assays. Brit J Haematol. 2004; 126:133–138.Google Scholar

Brodsky, RA. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008 Apr 15; 148(8):587–595.Google Scholar

Miyata, T, Takeda, J, Iida, Y, Yamada, N, Inoue, N, Takahashi, M, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993; 259:1318–1320.Google Scholar

Miyata, T, Yamada, N, Iida, Y, Nishimura, J, Takeda, J, Kitani, T, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994; 330:249–255.Google Scholar

Nagarajan, S, Brodsky, R, Young, NS, Medof, ME. Genetic defects underlying paroxysmal nocturnal hemoglobinuria that arises out of aplastic anemia. Blood. 1995; 86:4656–4661.Google Scholar

Mukhina, GL, Buckley, JT, Barber, JP, Jones, RJ, Brodsky, RA. Multilineage glycosylphosphatidylinositol anchor deficient hematopoiesis in untreated aplastic anemia. Br J Haematol. 2001; 115:476–482.Google Scholar

Luzzatto, L, Bessler, M, Rotoli, B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: A blessing in disguise? Cell. 1997; 88(January 10):1–4.Google Scholar

Medof, ME, Kinoshita, T, Nussenzweig, V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med. 1984; 160:1558–1578.Google Scholar

Rollins, SA, Sims, PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol. 1990 May 1; 144(9):3478–3483.Google Scholar

Rother, RP, Bell, L, Hillmen, P, Gladwin, MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005 Apr 6; 293(13):1653–1662.Google Scholar

Hall, SE, Rosse, WF. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood. 1996; 87:5332–5340.Google Scholar

Borowitz, MJ, Craig, FE, DiGiuseppe, JA, Illingworth, AJ, Rosse, W, Sutherland, DR, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4):211–230.Google Scholar

Brodsky, RA, Mukhina, GL, Nelson, KL, Lawrence, TS, Jones, RJ, Buckley, JT. Resistance of paroxysmal nocturnal hemoglobinuria cells to the glycosylphosphatidylinositol-binding toxin aerolysin. Blood. 1999; 93(5):1749–1756.Google Scholar

Brodsky, RA, Mukhina, GL, Li, S, Nelson, KL, Chiurazzi, PL, Buckley, JT, et al. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using fluorescent aerolysin. Am J Clin Pathol. 2000 Sep;114(3):459–466.Google Scholar

Araten, DJ, Nafa, K, Pakdeesuwan, K, Luzzatto, L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA. 1999 Apr 27; 96(9):5209–5214.Google Scholar

Hu, R, Mukhina, GL, Piantadosi, S, Barber, JP, Jones, RJ, Brodsky, RA. PIG-A mutations in normal hematopoiesis. Blood. 2005 May 15; 105(10):3848–3854.Google Scholar

Pu, JJ, Hu, R, Mukhina, GL, Carraway, HE, McDevitt, MA, Brodsky, RA. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica. 2012; 97(8):1225–1233.Google Scholar

Pu, JJ, Mukhina, G, Wang, H, Savage, WJ, Brodsky, RA. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia. Eur J Haematol. 2011 Jul;87(1):37–45.Google Scholar

Wiedmer, T, Hall, SE, Ortel, TL, Kane, WH, Rosse, WF, Sims, PJ. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993; 82(4):1192–1196.Google Scholar

Hugel, B, Socie, G, Vu, T, Toti, F, Gluckman, E, Freyssinet, JM, et al. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999 May 15; 93(10):3451–3456.Google Scholar

Ploug, M, Plesner, T, Ronne, E, Ellis, V, Hoyer-Hansen, G, Hansen, NE, et al. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood. 1992 Mar 15; 79(6):1447–1455.Google Scholar

Maroney, SA, Cunningham, AC, Ferrel, J, Hu, R, Haberichter, S, Mansbach, CM, et al. A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost. 2006 May;4(5):1114–1124.Google Scholar

Hillmen, P, Elebute, M, Kelly, R, Urbano-Ispizua, A, Hill, A, Rother, RP, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010 Aug;85(8):553–559.Google Scholar

Hillmen, P, Young, NS, Schubert, J, Brodsky, RA, Socie, G, Muus, P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006 Sep 21; 355(12):1233–1243.Google Scholar

Brodsky, RA, Young, NS, Antonioli, E, Risitano, AM, Schrezenmeier, H, Schubert, J, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008 Feb 15; 111(4):1840–1847.Google Scholar

Hillmen, P, Muus, P, Duhrsen, U, Risitano, AM, Schubert, J, Young, NS, et al. The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal hemoglobinuria (abstract). Blood. 2006; 106:40a–41a.Google Scholar

Saso, R, Marsh, J, Cevreska, L, Szer, J, Gale, RP, Rowlings, PA, et al. Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1999 Feb;104(2):392–396.Google Scholar

Suenaga, K, Kanda, Y, Niiya, H, Nakai, K, Saito, T, Saito, A, et al. Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria. Exp Hematol. 2001 May;29(5):639–642.Google Scholar

Brodsky, RA, Luznik, L, Bolanos-Meade, J, Leffell, MS, Jones, RJ, Fuchs, EJ. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct;42(8):523–527.Google Scholar

Diamond, LK, Blackfan, KD. Hypoplastic anemia. Am J Dis Child. 1938; 15:307.Google Scholar

Lipton, JM, Ellis, SR. Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis. Hematol Oncol Clin North Am. 2009; 23(2):261–282.Google Scholar

Narla, A, Ebert, BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010; 115(16):3196–205.Google Scholar

Sankaran, V, Chazvinian, R, Do, R, et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest. 2012; 122(7):2439–2443.Google Scholar

Fumagalli, S, Thomas, G. The role of p53 in ribosomopathies. Semin Hematol. 2011; 48(2):97–105.Google Scholar

Narla, A, Vlachos, A, Nathan, DG. Diamond Blackfan anemia treatment: past, present, and future. Semin Hematol. 2011; 48(2):117–123.Google Scholar

Zinsser, F. Atrophia cutis reticularis cum pigmentations, dystrophia unguium et leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi). Ikonogr. Dermatol. 1910; 5:219–233.Google Scholar

Savage, SA, Alter, BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009; 23(2):215–231.Google Scholar

Ballew, BJ, Savage, SA. Updates on the biology and management of dyskeratosis congenital and related telomere biology disorders. Expert Rev Hematol. 2013; 6(3):327–337.Google Scholar

Alter, B, Giri, N, Savage, S, et al. Malignancies and survival patters in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol. 2010; 150(2):179–188.Google Scholar

Lobitz, S, Velleuer, E. Guido Fanconi: a jack of all trades. Nat Rev Cancer. 2006; 6(11):893–898.Google Scholar

Bagby, GC, Alter, BP. Fanconi anemia. Semin Hematol. 2006; 43(3):147–156.Google Scholar

Garaycoechea, J, Patel, KJ. Why does the bone marrow fail in Fanconi anemia. Blood. 2014; 123(1):26–34.Google Scholar

Kupfer, GM. Fanconi anemia: a signal transduction and DNA repair pathway. Yale J Biol Med. 2013; 60(6):1291–1310.Google Scholar

Kee, Y, D’Andrea, D. Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest. 2012; 122(11):3799–3806.Google Scholar

Schwachman, H, Diamond, LK, Oski, FA, Khaw, KT. The syndrome of pancreatic insufficiency and bone marrow dysfunction. J Pediatr. 1964; 65:645–663.Google Scholar

Myers, KC, Davies, SM, Shimamura, A. Clinical and molecular pathophysiology of Schwachman-Diamond syndrome: an update. Hematol Oncol Clin N Am. 2013;(27):117–128.Google Scholar

Boocock, GR, Morrioson, JA, Popvic, M, et al. Mutations in SBDS are associated with Schwachman-Diamond Syndrome. Nat Genet. 2003; 33(1):97–101.Google Scholar

Wong, CC, Traynor, D, Basse, N, et al. Defective ribosome assembly in Shwachman-Diamond syndrome. Blood. 2011; 118(16):4305–4312.Google Scholar

Ballmaier, M, Germeshausen, M. Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost. 2011; 37(6):673–681.Google Scholar

Ballmaier, M, Germeshausen, M, Schulze, H, et al. C-MPL mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 2001; 97:139–146.Google Scholar

Al-Qahtani, . Congenital amegakaryocytic thrombocytopenia: a brief review of the literature. Clin Med Insights Pathol. 2010; 3:25–30.Google Scholar

DiMauro, S, Hirano, M. Mitochondrial DNA Deletion Syndromes. 2003 Dec 17 [Updated 2011 May 3]. In: Pagon RA, Adam MP, Bird TD, et al., editors. GeneReviews® [Internet]. Seattle, WA: University of Washington; 1993–2014. Available from: www.ncbi.nlm.nih.gov/books/NBK1203/Google Scholar

Rotig, A, Colonna, M, Bonnefont, JP, et al. A mitochondrial DNA deletion in Pearson’s marrow pancreas syndrome. Lancet. 1989; 333:902–903.Google Scholar

Cherry, AB, Gagne, KE, McLoughlin, EM, et al. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013; 31(7):1287–1297.Google Scholar

Boxer, LA. Severe congenital neutropenia: genetics and pathogenesis. Trans Am Clin Climatol Assoc. 2006; 117:13–32.Google Scholar

Horwitz, MS, Corey, SJ, Grimes, HL, et al. ELANE mutations in cyclic and severe congenital neutropenia. Hematol Oncol Clin N Am. 2013; 27:19–41.Google Scholar

Khincha, PP, Savage, SA. Genomic characterization of the inherited bone marrow failure syndromes. Semin Hematol. 2013; 50(4):333–347.Google Scholar

Albers, CA, Newbury-Ecob, R, Ouwehand, WH, et al. New insights into the genetic basis of TAR (thrombocytopenia-absent radii syndrome). Curr Opin Genet Dev. 2013; 23(3):316–323.Google Scholar

Weiss, G, Goodnough, LT. Anemia of chronic disease. N Engl J Med. 2005; 352(10):1011–1023.Google Scholar

Cartwright, GE, Lauritsen, MA, Jones, PJ, Merrill, IM, Wintrobe, MM. The anemia of infection. I. Hypoferremia, hypercupremia, and alterations in porphyrin metabolism in patients. J Clin Invest. 1946; 25(1):65–80.Google Scholar

Blanc, B, et al. Nutritional anaemias. Report of a WHO scientific group. World Health Organization Technical Report Series. 1968; 405:5–37.Google Scholar

Yip, R, Dallman, PR. The roles of inflammation and iron deficiency as causes of anemia. Am J Clin Nutr. 1988; 48(5):1295–1300. Epub 1988/11/01.Google Scholar

Guralnik, JM, Eisenstaedt, RS, Ferrucci, L, Klein, HG, and Woodman, RC. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood. 2004; 104(8):2263–2268.Google Scholar

Masson, C. Rheumatoid anemia. Joint Bone Spine. 2011; 78(2):131–137. Epub 2010/09/21.Google Scholar

Wilson, A, Reyes, E, Ofman, J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:44S–49S.Google Scholar

Piagnerelli, M, Vincent, JL. The use of erythropoiesis-stimulating agents in the intensive care unit. Crit Care Clin. 2012; 28(3):345–362, v. Epub 2012/06/21.Google Scholar

van Iperen, CE, van de Wiel, A, Marx, JJ. Acute event-related anaemia. Br J Haematol. 2001; 115(4):739–743. Epub 2002/02/15.Google Scholar

Sihler, KC, Napolitano, LM. Anemia of inflammation in critically ill patients. J Intensive Care Med. 2008; 23(5):295–302. Epub 2008/08/15.Google Scholar

Baer, AN, Dessypris, EN, Goldwasser, E, Krantz, SB. Blunted erythropoietin response to anaemia in rheumatoid arthritis. Br J Haematol. 1987; 66(4):559–564.Google Scholar

Means, RT Jr., Krantz, SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood. 1992; 80(7):1639–1647.Google Scholar

Koury, MJ, Ponka, P. New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr. 2004; 24:105–131.Google Scholar

Cartwright, GE, Lee, GR. The anaemia of chronic disorders. Br J Haematol. 1971; 21(2):147–152. Epub 1971/08/01.Google Scholar

Nemeth, E, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004; 306(5704):2090–2093.Google Scholar

Qiao, B, et al. Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin ubiquitination. Cell Metab. 2012; 15(6):918–924. Epub 2012/06/12.Google Scholar

Ross, SL, et al. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012; 15(6):905–917. Epub 2012/06/12.Google Scholar

Ganz, T, Nemeth, E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematol Am Soc Hematol Educ Program. 2011; 2011:538–542. Epub 2011/12/14.Google Scholar

Schwoebel, F, et al. The effects of the anti-hepcidin Spiegelmer NOX H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 2013; 121(12):2311–2315. Epub 2013/01/26.Google Scholar

Wang, W, Knovich, MA, Coffman, LG, Torti, FM, Torti, SV. Serum ferritin: past, present and future. Biochim Biophys Acta. 2010; 1800(8):760–769. Epub 2010/03/23.Google Scholar

Cash, JM, Sears, DA. The anemia of chronic disease: spectrum of associated diseases in a series of unselected hospitalized patients. Am J Med. 1989; 87(6):638–644.Google Scholar

Roy, CN. Anemia of inflammation. Hematology Am Soc Hematol Educ Program. 2010; 30:276–280.Google Scholar

Skikne, BS. Serum transferrin receptor. Am J Hematol. 2008; 83(11):872–85.Google Scholar

Marti-Carvajal, AJ, Agreda-Perez, LH, Sola, I, Simancas-Racines, D. Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis. Cochrane Database Syst Rev. 2013; 2:CD000332. Epub 2013/03/02.Google Scholar

Dallman, PR, Yip, R, Johnson, C. Prevalence and causes of anemia in the United States, 1976 to 1980. Am J Clin Nutr. 1984; 39(3):437–445. Epub 1984/03/01.Google Scholar

Price, EA, Mehra, R, Holmes, TH, Schrier, SL. Anemia in older persons: etiology and evaluation. Blood Cells Mol Dis. 2011; 46(2):159–165. Epub 2011/01/07.Google Scholar

Artz, AS, Thirman, MJ. Unexplained anemia predominates despite an intensive evaluation in a racially diverse cohort of older adults from a referral anemia clinic. J Gerontol A Biol Sci Med Sci. 2011; 66(8):925–932. Epub 2011 Jun 9.Google Scholar

Voulgarelis, M, Kokori, SI, Ioannidis, JP, Tzioufas, AG, Kyriaki, D, Moutsopoulos, HM. Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin. Ann Rheum Dis. 2000; 59(3):217–222.Google Scholar

Martinez-Lado, L, et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine (Baltimore). 2011; 90(3):186–193. Epub 2011/04/23.Google Scholar

Vincent, JL, et al. Anemia and blood transfusion in critically ill patients. J Am Med Assoc. 2002; 288(12):1499–1507. Epub 2002/09/24.Google Scholar

Sekeres, MA, Schoonen, WM, Kantarjian, H, List, A, Fryzek, J, Paquette, R, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. Journal of the National Cancer Institute. 2008; 100(21):1542–1551.Google Scholar

Rollison, DE, Howlader, N, Smith, MT, Strom, SS, Merritt, WD, Ries, LA, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008; 112(1):45–52.Google Scholar

Goldberg, SL, Chen, E, Corral, M, Guo, A, Mody-Patel, N, Pecora, AL, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010; 28(17):2847–2852.Google Scholar

Pedersen-Bjergaard, J, Daugaard, G, Hansen, SW, Philip, P, Larsen, SO, Rorth, M. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours. Lancet. 1991; 338(8763):359–363.Google Scholar

Liew, E, Owen, C. Familial myelodysplastic syndromes: a review of the literature. Haematologica. 2011; 96(10):1536–1542.Google Scholar

Hoffman, R. Hematology: Basic Principles and Practice. 5th ed. Philadelphia, PA: Churchill Livingstone/Elsevier; 2009:xxvii, 2523.Google Scholar

Hsu, AP, Sampaio, EP, Khan, J, Calvo, KR, Lemieux, JE, Patel, SY, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood. 2011; 118(10):2653–2655.Google Scholar

Bejar, R, Levine, R, Ebert, BL. Unraveling the molecular pathophysiology of myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(5):504–515.Google Scholar

Walter, MJ, Shen, D, Ding, L, Shao, J, Koboldt, DC, Chen, K, et al. Clonal architecture of secondary acute myeloid leukemia. The New England Journal of Medicine. 2012; 366(12):1090–1098.Google Scholar

Haase, D, Germing, U, Schanz, J, Pfeilstocker, M, Nosslinger, T, Hildebrandt, B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395.Google Scholar

List, A, Dewald, G, Bennett, J, Giagounidis, A, Raza, A, Feldman, E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. The New England Journal of Medicine. 2006; 355(14):1456–1465.Google Scholar

Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar

Papaemmanuil, E, Gerstung, M, Malcovati, L, Tauro, S, Gundem, G, Van Loo, P, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616–3627; quiz 99.Google Scholar

Haferlach, T, Nagata, Y, Grossmann, V, Okuno, Y, Bacher, U, Nagae, G, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014; 28(2):241–247.Google Scholar

Bejar, R, Stevenson, K, Abdel-Wahab, O, Galili, N, Nilsson, B, Garcia-Manero, G, et al. Clinical effect of point mutations in myelodysplastic syndromes. The New England Journal of Medicine. 2011; 364(26):2496–2506.Google Scholar

Yoshida, K, Sanada, M, Shiraishi, Y, Nowak, D, Nagata, Y, Yamamoto, R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478(7367):64–69.Google Scholar

Christiansen, DH, Andersen, MK, Pedersen-Bjergaard, J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001; 19(5):1405–1413.Google Scholar

Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood. 2016; 128(16):2096–2067.Google Scholar

Valent, P. Low blood counts: immune mediated, idiopathic, or myelodysplasia. Hematology/the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2012; 2012:485–491.Google Scholar

Arber, DA, Orazi, A, Hasserjian, R, Thiele, J, Borowitz, MJ, Le Beau, MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405.Google Scholar

Bejar, R, Greenberg, PL. The impact of somatic and germline mutations in myelodysplastic syndromes and related disorders. Journal of the National Comprehensive Cancer Network. 2017; 15(1):131–135.Google Scholar

Network NCC. National Comprehensive Cancer Network Guidelines: Myelodysplatic Syndromes Version 2.2014 275 Commerce Drive, Suite 300, Fort Washington, PA 190342013 Version 2.2014: Available from: www.nccn.org.Google Scholar

Cargo, CA, Rowbotham, N, Evans, PA, Barrans, SL, Bowen, DT, Crouch, S, et al. Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression. Blood. 2015; 126(21):2362–2365.Google Scholar

Kwok, B, Hall, JM, Witte, JS, Xu, Y, Reddy, P, Lin, K, et al. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance. Blood. 2015; 126(21):2355–2361.Google Scholar

Greenberg, P, Cox, C, LeBeau, MM, Fenaux, P, Morel, P, Sanz, G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6):2079–2088.Google Scholar

Garcia-Manero, G, Shan, J, Faderl, S, Cortes, J, Ravandi, F, Borthakur, G, et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008; 22(3):538–543.Google Scholar

Bejar, R, Stevenson, KE, Caughey, BA, Abdel-Wahab, O, Steensma, DP, Galili, N, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. Journal of Clinical Oncology. 2012; 30(27):3376–3382.Google Scholar

Greenberg, PL, Tuechler, H, Schanz, J, Sanz, G, Garcia-Manero, G, Sole, F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454–2465.Google Scholar

Greenberg, PL, Stone, RM, Al-Kali, A, Barta, SK, Bejar, R, Bennett, JM, et al. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2017; 15(1):60–87.Google Scholar

Hellstrom-Lindberg, E, Gulbrandsen, N, Lindberg, G, Ahlgren, T, Dahl, IM, Dybedal, I, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. British Journal of Haematology. 2003; 120(6):1037–1046.Google Scholar

Greenberg, PL, Sun, Z, Miller, KB, Bennett, JM, Tallman, MS, Dewald, G, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood. 2009; 114(12):2393–2400.Google Scholar

Passweg, JR, Giagounidis, AA, Simcock, M, Aul, C, Dobbelstein, C, Stadler, M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care–SAKK 33/99. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011; 29(3):303–309.Google Scholar

Malcovati, L, Porta, MG, Pascutto, C, Invernizzi, R, Boni, M, Travaglino, E, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005; 23(30):7594–7603.Google Scholar

Cutler, CS, Lee, SJ, Greenberg, P, Deeg, HJ, Perez, WS, Anasetti, C, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104(2):579–585.Google Scholar

Koreth, J, Pidala, J, Perez, WS, Deeg, HJ, Garcia-Manero, G, Malcovati, L, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2013; 31(21):2662–2670.Google Scholar

Silverman, LR, Demakos, EP, Peterson, BL, Kornblith, AB, Holland, JC, Odchimar-Reissig, R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2002; 20(10):2429–2440.Google Scholar

Kadia, TM, Jabbour, E, Kantarjian, H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Seminars in Oncology. 2011; 38(5):682–692.Google Scholar

Book contents

Section 3 - Specific Forms of Anemia

Access options

References

References

References

References

References

References

Further Reading

References

References

References

References

References

References

References

References

References

References

References

Book contents

Section 3 - Specific Forms of Anemia

Access options

References

References

References

References

References

References

Further Reading

References

References

References

References

References

References

References

References

References

References

References

Save book to Kindle

Save book to Dropbox

Save book to Google Drive